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Accessing Medicinally-Relevant Scaffolds 
Via Organocatalyzed Cascade Reactions 
By Joshua Hadley Jones
Advisor: Professor Stacey Brenner-Moyer
Abstract:  The  field  of  asymmetric  catalysis  embodies  the  efforts  of  chemists  to  mimic  the 
stereoselectivity routinely achieved by biological systems. Asymmetric organocatalysis, a sub-
field of asymmetric catalysis, is broadly based on the catalytic activity of non-transition metal, 
small molecules that transmit chirality to substrates. This  dissertation  describes  experimental 
work towards the construction of versatile, medicinally-relevant molecular scaffolds using chiral, 
diarylprolinol  silyl  ether  organocatalysts.  Specifically,  these  catalysts  were  used  in  1-pot, 
iminium-enamine  catalyzed  cascade  reactions  to  functionalize  α,β-unsaturated  aldehydes.  A 
comprehensive  review  of  iminium  and  enamine  organocatalysis  is  provided,  including  its 
development towards iminium-enamine cascade reactions. This review provides background for 
the  original  research  recounted  herein,  which  are  1)  Accessing  Medicinally-Relevant 
Cyclohexene  Scaffolds  via  a  Michael-Michael  Organocascade,  2)  One-Pot  Preparation  of 
Enantiopure  Fluorinated  β-Amino  Acid  Precursors,  and  3)  Accessing  Medicinally-Relevant 
Tetrahydrofuran Scaffolds via Organocascade Reactions.
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Chapter 1. 
 Introduction To Combining Organocatalyzed Reactions 
As Cascade Reactions And With Photoredox Catalysis
1.1 Organocatalysis
Beginning in the early 1970’s, but accelerating from the late 1990’s, a steady steam of robust, 
versatile organocatalysts have been introduced, many possessing the versatility and durability 
sought in previously established asymmetric methods (e.g., compared to inefficient resolution of 
racemates, or stoichiometric use of chiral auxiliaries).  Some merits of these catalysts include 
access to novel  reaction manifolds,  low sensitivity to water and oxygen,  reduced toxicity of 
catalyst residues, and a potentially reduced environmental impact of catalyst preparation.[1]  This 
introductory chapter offers an abbreviated narrative of this development, with special attention 
paid to those innovations most relevant to the original research presented in later chapters. 
Two of the earliest publications describing the use of amino acids for enantioselective bond 
formation  date  to  the  early  1970's,  an  era  in  synthetic  chemistry  fueled  by  the  tremendous 
commercial success of steroidal contraceptives (e.g., norethindrone).[2]  Efforts to access steroidal 
derivatives resulted in two industrial groups independently reporting (S)-proline in synthesizing 
a valuable steroid intermediate,  the Wieland-Miescher Ketone,  the absolute configuration of 
which  is  vital  for  downstream  targets.[3]  The  first  of  these  publications  demonstrated  an 
2
enantioselective Robinson Annulation, soon to be known by the authors’ namesake as the Hajos–
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Scheme 1.1: Early (S)-Proline-Catalyzed Aldol Reactions
The authors  experimented with  a  range of  conditions  and amino catalysts,  including the 
primary amino acids (S)-alanine and (S)-phenylalanine. However, (S)-proline (10 - 100 mol%) 
was reported to be most effective, with good yields (87%) and optical yield (84% ee), albeit with 
extended reaction times (72 hrs.)
Shortly  thereafter  (1974),  a  similar  (S)-proline  catalyzed  Aldol  condensation  achieved 
excellent yields (up to 100%) and enantioselectivity (up to 93% ee) while using lower catalyst 
loadings  (3  mol%)  (Scheme  1.1).[5],  [6]   The  authors’ meticulous  reaction  optimization  and 
verification of absolute configuration (by x-ray crystallography) provided valuable mechanistic 
insight  into  proline's  mode  of  substrate  activation  and  stereoinduction  (Scheme  1.2).[7] 
3
Condensation of  proline’s  pyrrolidine nitrogen with  a  carbonyl  carbon of  triketone 1.5  gave 
iminium intermediate 1.5i, whose equilibrium with enamine 1.5e drove the enantioselective aldol 
addition via combined enamine-Brønsted Acid activation and hydrogen-bonding stereoinduction 
to  give  chiral  ketol  1.7.   Subsequent  acid-catalyzed elimination  of  water  gave  condensation 
adduct 1.9.
The authors went on to comment on the bifunctional nature of proline as catalyst, describing 
both nucleophilic pyrrolidine and Brønsted Acid carboxylate. They demonstrated that proline's 
pyrrolidine core imparts sufficient nucleophilicity for rapid iminium formation with carbonyl 
carbons (compared to the less capable oxetane or piperidine equivalents), and that subsequent 
iminium-enamine equilibrium was a driving force for new C-C bond formation.  They went on to 
describe  proline's  carboxylate  moiety  to  act  as  a  multi-faceted  Brønsted  Acid  'co-catalyst', 
facilitating increased catalytic turnover, as well as promoting carbonyl activation and providing 
hydrogen-bonding stereoinduction.[8]  Although this early mechanistic proposal would be revised 
into  a  more  broadly  accepted  mechanism (via  a  Zimmerman-Traxler,  6-membered transition 
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Interestingly,  the  authors'  experience  with  semi-synthetic  chemistry  (contraceptives  were 
made  using  a  precursor  isolated  from  Mexican  Wild  Yams[2])  enabled  them  to  frame  the 
significance of their study in terms of chemical biology, noting:
"We  believe  that  our  results  may  be  considered  an  example  of  a  simplified  model  of  a 
biological system in which (S)-proline plays the role of an enzyme."  
This statement embodied a long-standing aspiration in chemical synthesis: to understand and 
harness  the  catalytic  activity  of  enzymes.[10]  In  retrospect,  this  foretold  a  renaissance  in 
asymmetric catalysis, with an increased knowledge of bio-catalysis providing inspiration for new 
enzyme catalysts, as well as biomimetic organocatalysts.[11]
Excepting  a  few notable  uses  of  proline,  and the  other  chiral,  small-molecules  as  chiral 
catalysts, a ‘re-discovery’ of proline-catalysis began in the late 1990’s, leading to an accelerated 
5
development of new organocatalysts in the coming decade.[12]  This increased interest in proline 
facilitated further details of proline’s interaction with carbonyls, affording researchers greater 
confidence to explore proline’s compatibility across diverse reaction manifolds.[13]  These studies 
showed proline to be compatible with a range of asymmetric reactions, including aldol-type, 
conjugate additions to enones, Mannich reactions, α-amination of aldehydes, and α−oxidation of 















































Figure 1.1: Examples of Proline-Catalyzed Reactions
Collectively,  these  experiments  represented  an  increased  acceptance  and  maturation  of 
proline-catalysis, more clearly drawing its boundaries, and providing criteria for the development 
of new organocatalysts.  These criteria encouraged more deliberate modifications to reactions 
6
conditions and to proline itself (or other chiral sources), thereby streamlining development of 
new organocatalysts.[15]
1.2 Types of Organocatalysts - Beyond Proline:
In 2008, Melchiorre, et. al. remarked on the rapid development of organocatalysis: 
"A  large  number  of  challenging  concepts  were  developed  independently  (and  almost 
simultaneously)  by  different  research  groups.  This  developed  into  tremendous  scientific 
competition  which  has  guided  asymmetric  aminocatalysis…and  opened  up  new  synthetic 
opportunities that were considered inaccessible only a few years before.[16]
Indeed,  the  coming  structural  innovations  in  aminocatalysis  would  naturally  utilize  the 
collective  experience  and  mechanistic  knowledge  gained  from  the  maturation  of  proline-
catalysis.  Specifically, proline-catalysis evolved into three distinct types of organocatalysts, with 
three  respective  modes  of  activation  and  stereoinduction:  1)  hydrogen-bonding  catalysis,  2) 
iminium  catalysis,  and  3)  enamine  catalysis.[16]   While  a  union  of  these  modes  in  proline 
facilitated effective chiral induction in select reactions, limitations arose due to the complexity of 
these  interactions,  as  well  as  proline’s  poor  solubility.[17]   Introducing  structural  changes  to 




Proline’s Zwitterionic character, although effective for stereoinduction, unfortunately results 
in poor solubility (i.e., ‘like brick dust’) in all but the most polar solvents (e.g., DMF, DMSO). 
This  obvious difficulty became the first  for  which solutions were devised.   Modifications to 
proline's  carboxylic  acid  moiety  improved  proline's  solubility  in  common  solvents  while 
maintaining  good  levels  of  hydrogen-bonding  stereoinduction  (Figure  1.2).[19]   One  notable 
modification was the conversion of proline’s carboxylate to a tetrazole (Figure 1.2, #1.18).[20] 
This both improved solubility in useful solvents (e.g., DCM, THF, MeCN), and maintained a 
hydrogen-bonding  mode  of  asymmetric  induction.  These  catalysts  proved  effective  in 







































Figure 1.2: Selected Proline-derived Hydrogen-Bonding Organocatalysts
1.4 Enamine & Iminium Organocatalysis
Organocatalysts with complementary, non-hydrogen bonding modes of stereoinduction were 
also (and continue to be) extensively pursued.  Many (but not all) of these catalysts are proline-
based,  with  enamine  /  iminium  varieties  typically  retaining  a  five-membered,  nucleophilic 
heterocycle  and  integrate  bulky,  inert  components  designed  to  transmit  chirality  by  steric 
influence.[22]
9
One  of  the  most  widely  employed  organocatalysts  is  the  MacMillan-type,  based  on  a 
versatile and easily accessible imidazolidinone skeleton derived from chiral amino acids (e.g., L-









These catalysts were developed with a focus on cycloaddition reactions, such as Diels-Alder 
reactions and nitrone cycloadditions.[24]  Aspects of Frontier Molecular Orbital Theory, such as 
LUMO-lowering (i.e.,  iminium-activation) and HOMO-raising (i.e.,  enamine activation) have 
been  useful  in  their  design  and  rationalization  of  stereochemical  outcomes.[25]   Due  to  their 
versatility across many iminium- and enamine -activated reactions, these catalysts have met with 



















































Figure 1.4: Selected Reactions Using MacMillan Organocatalysts
1.4.1 Jørgensen–Hayashi Organocatalysts
Another  useful  proline-derived  secondary  amine  organocatalyst  is  the  diarylprolinol  silyl 
ether  variety.[27]   Development  of  these  catalysts  was  influenced  by  the  parent,  unsilylated 
diphenyl prolinol derivative, employed in the Corey-Bakshi-Shibata (CBS) system for catalytic 
asymmetric reductions.[28]  These catalysts, commonly known by their inventors’ namesakes as 
11
the  Jørgensen-Hayashi  organocatalysts,  along with  the  MacMillan-type organocatalysts,  have 
been widely employed in the activation of aldehydes via iminium-enamine pathways (vide infra). 
Iminium-activated,  conjugate  additions  have  been  particularly  valuable  in  delivering 

























Scheme 1.3: Michael Reactions Catalyzed by Jørgensen–Hayashi Organocatalysts
A general mechanism for these conjugate additions begins with activation of enal substrate 
1.33  by  condensation  of  organocatalyst  1.32  to  form  the  reactive  iminium  species  1.33i. 
Conjugate addition (i.e.,  Michael Addition) of a nucleophile to the less hindered face of the 
substrate gives enantioenriched enamine intermediate  1.33e,  followed by catalyst  turnover to 
give the enantioenriched product aldehyde 1.34.
Jørgensen-Hayashi  organocatalysts  have  been  broadly  explored  in  the  iminium-enamine 
activation of α,β-unsaturated aldehyde (enal) substrates towards organocascade reactions.[30]  The 













































Scheme 1.4: General Mechanism For Iminium-Enamine Cascade Reactions
Progression through the first Michael addition occurs with iminium activation of starting enal 
1.33,  as  in  Scheme  2.   But  instead of  catalyst  turnover  to  provide product  1.34,  alternative 
reactivity is achieved in the presence of an electrophile capable of adding to the α-position of 
enamine 1.33e.  Enantioselective addition of the electrophile is from the sterically less-hindered 
face of  1.33e,  as  was the  conjugate  addition of  the  nucleophile  to  iminium 1.33i.  The only 
remaining  reactivity  for  iminium  intermediate  is  hydrolytic  catalyst  turnover  to  give 
enantioenriched aldehyde product 1.36.
1.5 Photoredox Catalysis:
As asymmetric organocatalysis matured from a niche application into a more commonplace 
methodology,  a  wealth  of  associated  reaction  data  helped  to  identify  conditions  where 
organocatalysis might be cross-compatible with other, achiral catalytic methods, such as certain 
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transition metal catalysis.[32]  For example, the use of chiral organocatalysts under the radical-
generating  conditions  of  photoredox  catalysis  has  recently  become  a  topic  of  considerable 
interest.[33]    Methods  for  radical  generation  and propagation  are  numerous,  but  visible-light 
photosensitizers (based both on transition-metals and organic dyes) do not require UV light to 
operate,  thus  reducing  the  likelihood  for  significant,  undesirable  side-reactions.[34]   This 
combination of organocatalysis with photoredox catalysis (i.e., Organophotoredox Catalysis) is 
thereby becoming a source of valuable asymmetric reactivity and mechanistic insight.[35]  In order 
to appreciate the current state of the art, a brief review of photoredox catalysis is provided, with 
special attention paid to organophotoredox catalysis. 
The  prototypical  photoredox  catalyst,  and  one  commonly  used  in  combination  with 
organocatalysts,  is  a  polypyridyl  complex  of  ruthenium,  tris(2,2′-bipyridine)  ruthenium(II), 
Ru(bpy)32+ (Figure 1.5).[36]  This catalyst has a long history in inorganic and physical chemistry, 
with  applications  broadly  inspired  by  biological  electron  transfers,  e.g.,  in  water-splitting, 
photovoltaic cells, energy storage and some notable polymerization applications.[37]  Of interest to 
synthetic organic chemists are both the visible-light excitation of Ru(bpy)32+ (~ 450 nm), which 
avoids higher-energy UV irradiation typical of much synthetic photochemistry, and the relatively 
long,  excited-state  lifetime  (~650-1100  ns,  solvent  dependent)  exhibited  by  this  and  related 
complexes.[38]   When  incorporated  into  organic  reactions,  these  long-lived  excited-states  can 






























Figure 1.5: Redox Potentials for Tris-Bipyridyl Ruthenium (II) Photoredox Catalysts
Figure 1.5: Both reductive and oxidative quenching mechanisms of Ru(bpy)32+
 result in net electron transfer from an electron donor (D) to an electron acceptor (A).
Since approximately 2008, increased research activity in photoredox catalysis has uncovered 
new and valuable  reactivities.[39]   A crucial  component  for  harnessing the  redox potential  of 
excited-state photosensitizers is a supply of electrons to be relayed between the excited-state 
photocatalyst  and  a  desired  substrate  (e.g.,  photoelectron  transfer  -  PET).[40]   Such  electron-
donors are often provided as sacrificial additives to a photoredox system.  Only in the presence 
of  such  additives  can  a  photoredox  catalyst  act  catalytically,  instead  of  being  consumed in 
uncontrolled redox processes.[41]  
Still,  a  productive photoredox system capable of converting the electrical  potential  of an 
excited-state photocatalyst into a desired transformation depends upon the matching of redox 
potentials between photocatalyst, additives, and substrate(s).[42]  For this purpose, detailed redox 
studies have been preformed on available photoredox sensitizers, including Ru(bpy)32+ (Figure 
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1.5).[43]  As indicated in Figure 1.5, irradiation of ground-state Ru(bpy)32+ generates excited-state 
Ru*(bpy)32+, which has the capacity for either oxidative or reductive transformations, depending 
on reaction conditions[44].  Oxidative conditions require an electron acceptor (A) to abstract an 
electron from excited-state Ru*(bpy)32+, generating Ru(bpy)33+ (-0.81 V), which, in the presence 
of  a  suitable  electron-donor  substrate  (D),  can  subsequently  be  reduced  (+1.29  V)  back  to 
Ru(bpy)32+, allowing re-entry into the catalytic cycle.[45]  The complementary reductive pathway 
requires inclusion of an electron donor (D) to generate Ru(bpy)3+ (+0.88 V), a powerful reductant 
(-1.31 V) capable of single-electron reduction of an electron-acceptor substrate (A). 
1.5.1 Additives in Photoredox Catalysis: 
Primary among the additives used to supply electrons to a (reductive) photoredox system are 
hindered,  tertiary  amines,  e.g.,  triethylamine  or  Hünig’s  base  (diisopropylethylamine).   An 
important criterion for selecting sacrificial electron donors is their vulnerability to side-reactions. 
Factors  effecting  the  reactivity  of  tertiary  aminium  radical  cation  intermediates  include  the 
degree  of  steric  hindrance  proximal  to  the  radical  (thus  discouraging  unwanted  radical 
couplings), as well as redox potentials of radical intermediates relative to photoredox catalyst.[46]
Apart from tertiary-amine additives, acidic additives have been used for substrate activation, 
more closely aligning the redox potentials between photocatalyst and substrate. Both Brønsted 

































Scheme 1.5: Tailoring Reaction Pathways Using Acidic Additives
Given the multi-component nature of photoredox catalysis, an important aspect of reaction 
optimization is identifying interactions (either synergistic or detrimental) between components in 
a reaction mixture.[48]   For example,  PET-generated radicals exhibit  reactivities influenced by 
their vicinal electronic environment (e.g., heteroatoms, pi-systems, etc.), especially their ionic 
character  (cationic  or  anionic).[49]   Moreover,   the  introduction  of  co-catalysts  (e.g.,  chiral 
organocatalysts;  vide  infra)  as  additives  in  photoredox  systems  can  further  complicate 
optimization efforts, not only in terms of reactivities but also conceptually.  For instance, the 
reactivity of radical couplings may not be well-described using the nomenclature of iminium-
enamine organocatalysis (e.g., nucleo- and electrophilicities, HOMO / LUMO activation).[50]  As 
a result, alternate terminology has been conceived to better describe and understand the ‘singly-
occupied  molecular  orbitals’  (SOMO)  that  radicals  can  possess,  such  that  ‘SOMO-philic’ 
describes a moiety’s preference for radical couplings.[51]
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1.6 Organophotoredox Catalysis
Although diastereoselectivity is commonly observed in photoredox catalysis due to stereo-
electronic factors, and improved selectivities have been seen using acidic additives (vide supra), 
enantioselective  induction  often  requires  a  chiral  co-catalyst,  such  as  organocatalysts  (i.e., 
organophotoredox catalysis).[52]
1.6.1 Iminium-Enamine Activation in Organophotoredox Catalysis
Although organophotoredox catalysis is still in its infancy, initial successes have focused on 
the α-functionalization of aldehydes via SOMO-activation of enamine intermediates (Scheme 
1.6).[53]  MacMillan’s mechanistic proposal involves generation of electron-deficient radical 1.47 
by PET from reductant Ru(bpy)3+, followed by coupling of 1.47 with SOMO-philic enamine 1.48 
to give stabilized radical 1.49. Loss of an electron by 1.49 to generate iminium intermediate 1.50, 
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Currently missing from organophotocatalytic methodologies is the iminium activation of an 
aldehyde or enal using a chiral, secondary amino-catalyst. The goal of such a reaction manifold 
would be the asymmetric radical-coupling between two electronically mismatched electrophiles 
analogous to Michael acceptors.  Although asymmetric conjugate addition to enones has been 
achieved using radical coupling, known methods are achieved using α-amino radicals, instead of 
the more distant (ɣ-amino) radical possibly compatible with currently known organophotoredox 
catalysis.[54]
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1.6.2 Hydrogen-Bonding Activation in Organophotoredox Catalysis
Hydrogen-Bonding organocatalysts have also been successfully applied to organophotoredox 
catalysis.   Although  a  detailed  review of  these  studies  is  not  crucial  for  understanding  the 
research contained herein, notable references are provided for the interested reader.[55]
1.7  Organocascade Reactions Applied to Organophotoredox Catalysis
Organocascade reactions can streamline synthetic protocols by increasing step- and atom-
economy.[56]  Although combining organocascades with photoredox catalysis has the potential to 
greatly  expand  the  utility  of  organophotoredox  catalysis,  few  methodologies  have  been 
communicated (Scheme 1.7).[57]  Following this precedent, an expanded integration of iminium-
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 Accessing Medicinally-Relevant Scaffolds via Organocascade Reactions
2.1 Carbocyclic Scaffolds via Iminium-Enamine Organocascades
Organocascade  reactions  can  increase  the  efficiency  of  chemical  synthesis  by  forming 
multiple,  chiral  bonds  in  1-pot  procedures[1].   As  such,  the  availability  of  organocascade 
methodologies are welcome complements to multi-step routes towards valuable core structures. 
An important application of iminium-enamine organocascades is in the synthesis of medicinally-
relevant carbocycles by the functionalization of activated alkenes (e.g., Scheme 2.1)[2].  
A notable example of organocascades’ utility for access to medicinally-relevant carbocycles is 
Hayashi’s synthesis of the anti-influenza drug ( ︎-)-oseltamivir (i.e., Tamiflu) using organocascade 
reactions (Scheme 2.2).[3]
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Development of related, iminium-enamine organocatalytic methodologies has facilitated (or 
expedited) the synthesis of valuable, medicinally-relevant scaffolds, especially chiral carbocycles 
(including heterocycles),  as  evidenced by  the  variety  of  therapeutic  targets  integrating  these 
scaffolds (Figure 2.1).[4], [5]  
A key synthetic step frequently used to initiate iminium-enamine organocascades is the β-
functionalization  of  enals  by  Michael  addition  of  nucleophiles.[6]   Given  the  inclusion  of  a 
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suitable electrophile, this initial step can be rapidly followed by electrophilic α-functionalization 
of the same substrate.[7]
2.2 Michael-Initiated Organocascades For Accessing Carbocycles
Organocatalyzed Michael reactions can provide high yields and enantioselectivities and are 
useful not only for access to valuable β-amino acid analogues, but more generally as the initial 
step  towards  generating  greater  molecular  complexity  in  iminium-enamine  organocascade 
reactions.  Many reaction pathways exist for extending organocatalyzed Michael reactions to 
encompass α,β-functionalization of the same substrate in 1-pot procedures.  A number of these 
methods are discussed below, especially those relevant to the reports contained in the following, 
experimental chapters (Ch. 3-5).
2.2.1 Cyclopentanes and Cyclohexenes via Michael-Michael Organocascades
Among potential  nucleophiles for  initiating iminium-activated organocascade reactions of 
α,β-unsaturated  aldehydes  are  1,3-dicarbonyl  compounds.[8]   For  example,  1,3-dicarbonyl 
compounds have been useful as Michael-donors for the creation of functionalized 5-membered 
carbocycles (Scheme 2.3).  The mechanism of this reaction proceeds first by activation of α,β-
unsaturated aldehyde 1.33 by catalyst 1.32 towards nucleophilic attack by 1,3-dicarbonyl 2.3. 
Approach of enol 2.3e from the re-face of iminium-activated aldehyde 1.33i allows for the first 
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Michael  addition.   Intermediate  enamine  2.4e  then  undergoes  an  intramolecular  Michael 
addition, providing the 5-membered ring product 2.5.





































up to 20:1 d.r.
84-99% ee
In  the  interest  of  producing  functionalized,  chiral  cyclohexenes  via  a  similar,  Michael-
Michael organocascade methodology, it was that found that repositioning the Michael acceptor 
relative to the 1,3-dicarbonyl unit (Figure 2.2, 2.3 vs. 2.6) provided a template for accessing the 
desired, highly-functionalized, enantioenriched cyclohexenes  (Scheme 2.4).[9]
29
An overview of the accepted mechanism for forming these cyclohexenes is depicted below 
(Scheme 2.4).  Organocatalyst 1.32 reacts with α,β-unsaturated aldehyde 1.33 to form iminium 
intermediate  1.33i,  which  is  subsequently  attacked  by  enol  2.6e  to  give  the  1st  Michael 
intermediate 2.7e.  A second, intramolecular Michael addition occurs when the enamine, Michael 
donor  moiety of 2.7e attacks the adjacent 4-position of the enone, Michael acceptor moiety, 



















































up to 98:2 d.r.
up to 99% ee
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2.2.2 Cyclohexenes via Michael—Morita-Baylis-Hillman Organocascades
Another possibility mode of reactivity for completion of Michael-initiated organocascades is 
the  Morita-Baylis-Hillman  (MBH)  reaction  (Scheme  2.5).[10]   Activated  Michael  acceptor, 
iminium 1.33i,  reacts  stereoselectively  with  nucleophilic  Michael  donor  2.10e to  give  chiral 
intermediate enamine 2.11.  Catalyst release is followed by an intermolecular conjugate addition 
of the free organocatalyst to intermediate 2.12.  This forms 2.13e, which, rather than undergoing 
a second Michael addition, is transformed by an intramolecular Morita-Baylis-Hillman reaction. 
Notably, the MBH pathway requires a proton at the α-position of Michael acceptor 2.12, because 
removal of this proton is necessary to liberate the catalyst and form products 2.15.
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up to 69% yield
92-98% ee
2.2.3 Cyclohexenes via Michael-Acetalization Organocascades 
Yet  another  viable  pathway  for  Michael-initiated  organocascades  is  the  Michael-
Acetalization pathway, valuable for introducing oxygen into cyclic structures (Scheme 2.6).[11] 
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Mechanistically, the enol of β-ketoester 2.6e attacks iminium-activated Michael acceptor 1.33i to 
give intermediate enamine 2.7e.   A potential  intramolecular second Michael addition to give 
Michael-Michael product 2.9 (as in Scheme 2.4) is precluded (due to functionalization of the β-
ketoester by R1=aryl), instead permitting equilibration of keto-enamine 2.7e with enol-iminium 
2.7i to facilitate the intramolecular acetalization reaction to give intermediate acetal 2.16, which, 
with assistance from acid additive (4-nitrobenzoic acid), is hydrolyzed to furnish heterocyclic 
product 2.17.[12]
2.3 Organocatalytic Olefin Amino-Fluorinations
Organic molecules containing fluorine are rare in nature as a consequence of fluorine’s high 
electronegativity and reactivity.[13]  Fortunately, this reactivity has leant the synthetic chemist a 
useful hand in forming carbon-fluorine bonds.  From the 1950s, the inclusion of fluorine into 
organic chemistry has represented a major synthetic effort, with products that are ubiquitous in 
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daily  life  (e.g.,  fluorinated  polymers,  refrigerants,  solvents,  surfactants,  anesthetics, 
pharmaceuticals).[14]  The development of safe and efficient fluorination reagents and protocols 
has revealed the profound changes fluorine can impart to the physical, chemical and biological 
properties of a molecule.[15]  As a result (and more recently), an increased demand for regio-, 
chemo-, and enantioselective inclusion of fluorine into medicinal targets has driven the expanded 
availability of bench-stable, mild, chemoselective fluorinating reagents.[16] 
The formation of carbon-fluorine bonds for the fine-chemicals’ markets is accomplished by 
both electrophilic and nucleophilic fluorinating reagents (Figure 2.3).  
These reagents have been devised in order to avoid working directly with F2 (and other highly 
reactive  fluorinating  agents  such  as  HF),  whose  extreme  reactivity  is  a  danger  to  valuable 
substrates and invaluable chemists alike. Nucleophilic fluorinating reagents (NFR) provide an 
electron-rich  environment  to  increase  the  nucleophilicity  of  the  attached  fluorine  atom(s),  a 
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challenge  (even  with  electrochemical  methods)  due  to  fluorine’s  high  electronegativity. 
Electrophilic  fluorinating  reagents  (EFRs)  typically  possess  a  fluorine-nitrogen  bond,  with 
vicinal  electron-withdrawing  groups  (e.g.,  R-SO2)  allowing  fluorine  to  act  as  electrophile. 
Notably, the development of EFRs has provided important complementary reactivity to NFRs, 
and has stimulated enantioselective fluorinations mediated by 2o amino organocatalysis.[17]
These technologies have not only provided new synthetic knowledge regarding the safe and 
effective formation of carbon-fluorine bonds, but also have revealed how those carbon-fluorine 
bonds  can  radically  alter  in  vivo  characteristics  of  drugs  compared  to  their  non-fluorinated 
counterparts.[18]  Specifically, the basicity of neighboring amines is decreased, the electrophilicity 
of  carbonyls  is  increased and the lipophilicity of  proximal  groups can be modified with the 
inclusion of fluorine. These and other effects have allowed medicinal chemists to tailor properties 
related to solubility, CNS penetration, metabolic stability and binding-site affinity.[19]
Accessing enantiopure  difluoroamines  has  largely  been achieved using racemic  methods, 
which  may  necessitate  inefficient  separation  of  enantiomers  and  are  typically  less  atom-
economical than stereoselective methods (vide infra).  In order to appreciate the optimization 
necessary for developing these organocascades, it is helpful to examine the individual cascade 
components: first, the organocatalyzed aza-Michael reaction.
2.3.1 Aza-Michael Reactions
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Nitrogen-containing organic molecules are vital to biological systems and are therefore are a 
dominant functionality in medicinal chemistry.[20]  Organocatalyzed Aza-Michael reactions offer 
access to a variety of highly enantio-enriched β-Amino carbonyl compounds and derivatives, 
among many other valuable scaffolds.[21]  However, the introduction of nucleophilic nitrogen as a 
Michael-donor,  especially  in  the  presence  of  another  nucleophilic  heterocyclic  amino 
organocatalyst, can be challenging due to the potential for racemization.  Racemization can occur 
either as a result of competition for iminium formation with the desired enal substrate, or as a 
result of adventitious nucleophilicity towards the 4-position of the enal substrate before being 
activated by the chiral catalyst.[22]  An example of a successful Aza-Michael design can be seen in 
Scheme 2.7.[23]  
2.3.2 α-Fluorination of Aldehydes 
Fluorine’s high electronegativity creates a challenge for the stereoselective α-fluorination of 
aldehydes, largely due to the higher enol (enamine) tendency of the product, which results in an 
increased potential for racemization, as well as difluorination side-reactions.[24]  These difficulties 
have been largely overcome by the judicious optimization of reaction conditions (e.g., via choice 
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of  solvents  and  work-up  protocols)  to  achieve  the  desired  organocatalytic,  enantioselective 
mono-fluorinations of aldehydes (Scheme 2.8).[25]












































2.3.3 Accessing β-fluoroamines Using Enal Substrates 
Following reports of the aforementioned, organocatalytic β-aminations and α-fluorinations, 
several groups took the opportunity to combine these motifs for accessing chiral β-fluoroamines 
(Scheme 2.9).[26]  Mechanistically, enal 1.33 (Scheme 2.9), in the presence of iminium-enamine 
organocatalyst 1.32 (20 mol%), forms activated iminium intermediate 1.33i, a highly reactive 
Michael acceptor.  This intermediate rapidly undergoes enantioselective conjugate addition by 
nucleophilic,  CBz-protected  methoxyamine  2.18  to  give  intermediate  amino-enamine  2.22e. 
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Addition of electrophilic fluorinating reagent NFSI to the reaction mixture promotes subsequent, 
stereoselective α-fluorination of 2.22e, followed by hydrolytic catalyst turnover to give enantio-
enriched α-fluoro-β-amino aldehyde 2.23.  Reduction to alcohol 2.24 (to avoid racemization of 
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Scheme 2.9: Organocatalytic Access to Aliphatic β-Fluoroamines
2. NaBH4
9 examples
up to 79% conversion
up to 98:2 d.r.
>99% ee
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2.3.4 Organocascade Access to !,!-difluoroamine Scaffolds
Following this accomplishment,  pursuit  of  an optimized,  organocatalytic route to another 
useful  (but  less  utilized)  functionality,  the  chiral  β,β-difluoroamine  moiety,  ensued. 
The β,β-difluoroamine functionality is seen is several drugs and drug candidates (Figure 2.4).[27]   
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Although methods for the synthesis of β,β-difluoroamines have existed prior to the latest, 
enantioselective  versions,  their  poor  atom-economy  and  narrow  scope  has  hindered  greater 
utilization of this functionality (Scheme 2.10).[28]
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Method (A)  is catalytic, highly enantioselective and high yielding but fails to incorporate 
R=alkyl into its scope.  Method (B) is not stereoselective in the reductive amination, which may 
necessitate low-yielding separation of diastereomers.  Method (C) is not catalytic, and requires 
use  of  chiral  starting  materials,  and  is  furthermore  prone  to  racemization  during  synthesis. 
Although each of these methods is valuable, none provides chiral products from aliphatic enals, a 
class of common and inexpensive precursors.  Despite the availability of these methods, the need 
for  chiral,  aliphatic  β,β-difluoroamines  in  medicinal  chemistry  successfully  motivated  the 
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extension  of  β-fluoroamine  syntheses  towards  a  catalytic,  enantioselective  method  for  β,β-
difluoroamines, especially for incorporating aliphatic enals as synthons  (Scheme 2.11).[29]  
Mechanistically,  following  enantioselective  aza-Michael  addition  of  nucleophilic  CBz-
protected methoxyamine 2.18  to enal  1.33 (as in Scheme 2.9),  addition of racemic,  proline-
derived organocatalyst 1.32r (20 mol% of starting enal),  as well  as electrophilic fluorinating 
reagent  NFSI  (2  equiv.)  drove  the  difluorination  component  of  the  cascade  reaction  to 
completion.   Reductive  work-up  gave  good  conversion  to  enantio-enriched,  aliphatic,  α,α-
difluoro-β-amino alcohol products 2.34, with good to excellent ee values.
2.4 Accessing Enantioenriched Tetrahydrofuran Scaffolds
Substituted tetrahydrofurans (THFs) are common structural cores in natural products, and 
consequently have some importance in medicinal chemistry.[30]  Given the prevalence of these 
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structural cores, synthetic methods for accessing them are continually being improved, especially 
for  stereoselective  functionalization.[31]   Methods  providing  diastereoselectivity  include  the 
photoredox catalyzed cyclizations of enones (Scheme 2.12).[32]  
Enantiospecific and enantioselective methods are also known, but they often use methods 
with  poor  atom-economy,  such  as  with  chiral  auxiliaries,  or  ligand-based,  transition-metal 
catalyzed processes.[33]  An enantioselective organocatalytic method is also known, but despite 
excellent ee-values, yields were only fair to good (Scheme 2.13).[34]  
Despite  the  myriad  of  methods  for  constructing  functionalized  tetrahydrofurans, 
opportunities persist for improved yields and enantioselectivities.  Future successes may involve 
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the catalytic formation of two or more bonds in one-pot reactions, especially those with high 
chemo-, regio-, and stereoselectivities.  In this vein, methods arising from recent advances in 
organophotoredox catalysis may be contenders for providing such needed routes. 
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Accessing Medicinally-Relevant Cyclohexene Scaffolds 
via a Michael-Michael Organocascade 
3.1 Introduction
Chapter  2  introduced aspects  of  organocatalyzed cascade reactions,  specifically  those 
involving  iminium-enamine  activation  of  α,β-unsaturated  aldehydes  (enals)  catalyzed  by  the 
diphenyl prolinol silyl ether catalysts (Jørgensen-Hayashi catalysts).  Among potential building 
blocks  compatible  with  these  reaction  manifolds  are  readily  accessible  1,3-dicarbonyl 
compounds (also discussed in Ch.2), which have been used as nucleophilic Michael donors in 
conjugate  addition  reactions.[1]   Certain  1,3-dicarbonyls,  namely  β-ketoesters  with  α,β-
unsaturation,  possess  Michael  donor  as  well  as  Michael  acceptor  functionalities.   This 
combination of functionality is useful for cascade reactions as multiple, complementary reactive 
sites are made available within the same substrate.  However, the synthetic potential for this type 
of β-ketoester has been less realized with Jørgensen-Hayashi organocatalysts in Michael-Michael 
cascade reactions for the construction of functionalized, chiral 5- and 6-membered carbocycles 
(Schemes  2.3  and  2.5).[2]   In  the  interest  of  expanding  the  potential  of  these  substrates  in 
organocascade reactions, a reaction manifold was designed for the formation of functionalized 
cyclohexenes using Jørgensen-Hayashi organocatalysts to activate β-ketoesters for the Michael-
Michael organocascade reactions described below.
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In  the  course  of  development  of  the  aforementioned  Michael-Michael  organocascade 
reactions,  an  interesting  aspect  of  substrate  modification  was  explored  that  involved  the 
placement of the Michael acceptor moiety at different positions of the β-ketoester substrate (as in 
Figure 2.2 and Figure 3.1, structures 2.3 vs. 2.6).[2c], [3]
However, structure 2.6, otherwise known as a Nazarov reagent, although allowing for the 
initial  Michael  addition to occur,  rather than facilitating a second Michael  addition,  saw the 
organocatalyst act as an adventitious Michael donor, attacking the conjugate position of the β-
ketoester and initiating an unexpected Morita-Baylis-Hillman reaction (Scheme 3.1).
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Scheme 3.1 displays an intramolecular Morita-Baylis-Hillman (MBH) reaction, initiated by 
a stereoselective reaction between organocatalyst 1.32 and conjugate position of intermediate β-
ketoester 3.2.  Following this organocatalyzed MBH reaction, catalyst release provides product 
carbocycle 3.3.  Interestingly, this Michael-MBH pathway requires a proton at the α-position of 
β-ketoester 3.4 (Scheme 3.2),  because removal of this proton is necessary to liberate the catalyst 
and form stable, isolable products 3.5e. 
Building  on  this  observation,  when  aryl-substituted  β-ketoester  Michael  donor  2.6  was 
subjected to similar conditions, a Michael-acetalization cascade was observed (Scheme 3.3).[4] 
The authors provided a rationale for the acetalization pathway, noting that aryl-substitution of β-
ketoester  substrate  2.6  afforded  extended  conjugation,  and  associated  thermodynamic 
stabilization, to hemi-acetal product 2.17. 
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Although  an  iminium-catalyzed  Michael-Michael  route  to  cyclohexenes  via  β-ketoester 
substrates  had  not,  thus  far,  been  realized,  clues  contributed  by  optimization  of  the 
aforementioned  Michael-initiated  organocascades  sufficed  for  development  of  an  analogous 
Michael-Michael route to the desired cyclohexene scaffolds (Scheme 3.4).[5]  Instrumental to this 
methodology was replacement of the proton necessary for the Michael-MBH reaction (Scheme 
3.2) with cyclic alkyl member extending between the α- and β-positions of β-ketoester substrate 
3.6.  This substrate modification completely precluded the MBH pathway previously reported, 
thereby leaving open the Michael-Michael manifold and providing the desired bicycles 3.7e in 
good yields and excellent diastereomeric ratios and enantiomeric excesses.  
Mechanistically (Scheme 3.5), catalyst 1.32 reacted with cyclic enal substrate 3.8 to form 
iminium  1.33i,  which  was  subsequently  attacked  by  Michael  donor  3.8e  to  give  activated-
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enamine 3.9e.  Due to the absence of a proton alpha to the ketone functionality in 3.9e, the MBH 
pathway was suppressed and no Michael-MBH product (3.10) was reported.  Additionally, the 
undesired  acetalization  reaction  was  discouraged,  possibly  due  to  absence  of  extended 
conjugation of the aryl moiety present in the Michael-Acetalization studies.  Indeed, a second 
Michael addition was favored, providing carbocyclic iminium species 3.11i, which was readily 
hydrolyzed to give bicyclic product 3.12. 
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Furthermore,  the  use  of  trifluoroethanol  as  solvent  was  crucial  for  the  Michael-Michael 
cascade.  This highly polar, protic solvent provided strong hydrogen-bonding interaction with the 
β-ketoester, activating it toward the second conjugate addition (Scheme 3.6).
While a cyclic olefin (as in Scheme 3.5, #3.8), had been shown to participate in a Michael-
Michael cascade to form 6-membered carbocycles, it had yet to be determined whether acyclic 
olefins (as in Scheme 3.8, #2.6)  could also form 6-membered rings via the Michael-Michael 






































Will Acyclic β-Ketoesters Form Cyclohexenes via Michael-Michael Cascades?





3.2 Results And Discussion
3.2.1 Initial Cascade Reaction
From the studies previously described (e.g. Michael-Michael cascades for 5-membered rings, 
Michael-MBH and Michael-acetalization cascades for 6-membered rings),  it  was known that 
multiple pathways for organocatalyzed cascades were possible. But the question was whether the 
Michael-MBH reaction could be avoided with acyclic β-ketoesters by choosing the right reaction 
conditions (Scheme 3.8).  Studies were undertaken to explore this possibility.
Initial conditions (Entry 1, Table 3.1) revealed a good conversion to the desired Michael-
Michael products (87%), with low yields of MBH by-products (13%).  Enantioselectivity of the 
major desired diastereomer was 93%. Additional conditions were explored that might further 
suppress the MBH reaction, i.e., by suppression of the intermolecular reaction between catalyst 
1.32 and intermediate 3.2 (Scheme 3.1). These conditions included dilution and reduced catalyst 
loading (Entries 1-3, Table 1). Next, the influence of additives known to affect catalyst turnover 
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(such  as  molecular  sieves,  and  an  acid  additive)  was  explored  (compare  Entry  1  vs.  4-6). 
Exploration  of  these  variables  revealed  that  our  original  reaction  conditions  were  optimal 
(Entries 2-6, Table 3.1).
a Reaction Conditions: 3.16 (1 equiv), 3.17 (1 equiv), cat. 1.32 (10 mol %), CF3CH2OH (0.3 M), rt. b determined by 
1H NMR of crude reaction mixture. c determined by chiral HPLC.
With  this  data  in  hand,  alternate  means  of  suppressing  the  MBH reaction  were  sought. 
Reducing the nucleophilicity of the catalyst could potentially suppress conjugate addition of the 
catalyst to Michael acceptor 3.2, thereby discouraging the MBH reaction (Scheme 15). Thus, we 
tried an electron deficient catalyst.  This reduced the activity of the catalyst;  after 8 days the 
reaction showed almost no conversion to the desired products (compare Entries 1 vs. 2, Table 
3.2).  As  an  alternate  means  of  reducing  catalyst  nucleophilicity,  catalysts  with  larger  silyl 
protecting groups (e.g.,  TBDMS, TES, TIPS) were tried.  This  resulted in lowered ee of  the 
desired products (compare entries 1 with 3-5, Table 3.2). Thus, it was decided that the initial 












































a Reaction Conditions: 3.16 (1 equiv), 3.17 (1 equiv), 3.20 (10 mol %), CF3CH2OH (0.3 M), rt.  b determined by 1H 
NMR of crude reaction mixture.  c determined by chiral HPLC 
3.2.2 Separation of Diastereomers and NMR Interpretation
Separation of the desired Michael-Michael products from the MBH side product required 
silylation of the desired product enol followed by chromatography  (Scheme 3.9).  The MBH 
product (3.19A) was not silylated at the enol, possibly due to steric hindrance of the adjacent 
alkyl  group.   This  allowed  for  facile  separation  of  the  silylated,  desired  Michael-Michael 
products (B’, C’, D’) from the unsilylated, undesired MBH product. Desilylation of the isolated 
desired products using TBAF provided the desired diastereomers. The major diastereomers (B 
and its epimer, C) were separable in some, but not all, cases from the minor diastereomers (D 

























Conversionb: all (3.18 + 3.19)
100% (87% + 13%
(poor)
97% (89% + 8%)
100% (89% + 11%)
98% (91% + 7%)































































Scheme 3.9: Separation of Diastereomers
Products were identified by NMR spectroscopy. Specifically, the aldehyde and enol regions 
of the spectrum were useful in confirming the presence of the desired products in the crude 
reaction mixture (3.18B, C,  D and  DT  in Figure 3.2). Careful chromatography and silylation 
allowed for isolation of each product, and identification of each peak in the enol region with a 
corresponding  enol  peak.  The  side  product  with  an  enol  peak  (~  12.9ppm)  that  lacked  a 




It was determined that C was the epimer of B by re-subjecting pure C to the catalyst and 
CF3CH2OH, which gave a mixture of C and B. When D was subjected to the same conditions, a 
mixture of D and DT was not obtained. However, upon prolonged storage (3-4 weeks) at -30oC, 
pure D did become a mixture of D and DT. We speculate that D and DT are related as tautomers, 
and are diastereomers of B/C at the second Michael addition. In one case (Table 3.3, Entry 6), D 
was  the  major  diastereomer,  so  decomposition,  or  products  other  than  the  desired  Michael-
Michael cascade products, could be ruled out. 
3.2.3 Substrate Scope






































































































a Reaction Conditions: 1.33 (1 equiv), 3.21 (1 equiv), 1.32 (10 mol %), CF3CH2OH (0.3 M), rt. b Yield = isolated 
yield of B+C+D. Conversion, dr, and ratio of α:β determined by 1H NMR. ee determined by chiral phase HPLC. dr 
= ratio of MAJOR:MINOR.  c C is the major epimer. d D is the major epimer.
This substrate scope revealed this reaction to work well with alkyl substituted β-ketoesters, and 
electron deficient and electron neutral aryl substituted α,β-unsaturated aldehydes (Entries 1 & 2, 
Table 3.3). Shockingly, when the same aryl substituted β-ketoester that exhibited Michael-
acetalization cascade reactions[4] were subjected to our reaction conditions, only the Michael-
Michael product was observed (Entry 5, Table 3.3; Scheme 3.10).
With  this  realization,  further  substrates  were  explored  with  aryl-substituted  β-ketoesters 
(Entries 4-11, Table 3.3). Due to the complete absence of MBH and acetalization products, the 
reaction  favors  aryl  over  aliphatic  substituted  β-ketoesters.  The  aromatic  groups  provide 















































ketoesters as Michael acceptors for the second Michael addition. Due to the absence of side-
products  (i.e.,  MBH  and  acetalization),  aryl  substituents  greatly  simplified  purification  and 
allowed  for  yield  determination.  Moderate  yields  for  an  ortho-fluoro-phenyl  substituted  β-
ketoester  (Entry  9)  showed  the  reaction’s  tolerance  for  ortho  substituents.  Using  the 
electronically  neutral  phenyl  substituted  β-ketoester,  various  groups  were  tolerated  at  the 
aldehyde (entries 4-9). Substituting an aryl for an ester group at the aldehyde (entry 6) was also 
well tolerated. An unsubstituted β-ketoester performed poorly (Entry 12), however, giving only 
12% conversion after  3 days.  An electron rich aryl-substituted aldehyde,  combined with the 
original alkyl substituted β-ketoester, was not well-tolerated giving 50%conversion after 7 days 
(entry 13).  
3.3 Conclusions
The key result  from this  work has been the observation that  a  simple change in solvent 
(CF3CH2OH vs. CH2Cl2) can have a dramatic effect on the outcome of these cascade reactions. 
On the one hand, it was shown by Gong[4] that use of CH2Cl2 provides a Michael-acetalization 
cascade in moderate yield (up to 78%) and excellent enantioselectivity (up to 99%) (3.21 —> 
3.23, Scheme 3.10).  On the other hand, our research has shown that use of CF3CH2OH with the 
same substrates and the same catalyst led to Michael-Michael cascade products with good to 
excellent  yield  and  excellent  enantioselectivity  (3.21  —>  3.18,  Scheme  3.10).  The  use  of 
trifluoroethanol as solvent was critical for the prevention of acetalization side-reactions. This was 
due to suppressing keto-enol tautomerization of the single-Michael intermediate (3.24 3.25, 





































Scheme 3.11: Suppression of Acetalization With CF3CH3OH
A further significant result of this research is the fact that while the Brenner-Moyer lab has 
previously reported the formation of 6-membered carbocycles using cyclic  β-ketoesters[5],  we 
have extended this methodology to a general Michael-Michael cascade tolerating cyclic, acyclic, 
aryl and alkyl substituted β-ketoesters. 
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Chapter 4. 
One-Pot Preparation of Enantiopure Fluorinated β-Amino Acid Precursors 
4.1 Introduction
As introduced in Ch.2, methods for synthesizing chiral β,β-difluroamines often hinge on the 
availability of enantiomerically pure precursors or, in their absence, expensive chiral auxiliaries 
for diastereoselective bond-formation.[1] Lacking these options, racemic mixtures can be resolved 
to attain the desired enantiomer, typically resulting in a material loss of at least 50%.[2] None of 
these  options  is  ideal,  especially  considering  the  recently  available  options  for  the 
enantioselective fluorination of aldehydes and amino-fluorination of alkenes.[3] Following reports 
of organocatalytic β-aminations and α-fluorinations[4], the Brenner-Moyer group combined these 
motifs to report an organocascade reaction for the α-fluoro-β-amino functionalization of α,β-
unsaturated aldehydes to give β-fluoroamines (Scheme 4.1).[5]  Furthering this line of research, 
































































R = aliphatic groups
Although enantioselective methods exist for attaining the same (see Ch.2, section 3.4), none 
provides  chiral  products  from  achiral,  aliphatic  enals,  a  class  of  common  and  inexpensive 
precursors.  The  aim  of  this  project  has  been  to  modify  our  organocascade  β-fluoroamine 
synthesis  to  produce an enantioselective olefin amino-difluorination compatible  with a  broad 
range of aliphatic substrates. 
4.2 Results And Discussion 
4.2.1 Initial Results
Initially,  a  general  synthetic  method  was  proposed  for  the  desired  amino-difluorination 
organocascade based on the Brenner-Moyer lab’s prior amino-fluorinations[5]  (Scheme 4.2).  It 
was imagined that aliphatic enal substrate 1.33, activated by secondary amine catalyst 1.32 to 
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give iminium 1.33i,  would undergo conjugate addition by amine nucleophile 2.18  to give β-
amino enamine 2.22e,  which, in the presence of electrophilic fluorinating reagent NFSI, was 
known  to  give  mono-fluorinated  enamine  intermediate  2.33e.  In  the  presence  of  a  second 
equivalent of NFSI, mono-fluoro enamine 2.33e was reasonably expected to convert to amino-
difluoro iminium intermediate 4.3i, which could then be hydrolyzed prior to reductive work-up 












































1. (i) t-BuOMe (0.625 M)
       1.32 (20 mol%)
    (ii) t-BuOMe (0.25M)













Due to previous experience in the Brenner lab with this type of reaction, we expected the 
optimization would be relatively straightforward. We were optimistic specifically because, due of 
fluorine’s  strong inductive  effect,  the  α-proton of  the  mono-fluorinated intermediate  is  more 
acidic than the non-fluorinated counterpart. This has previously led to either racemization of the 
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C-F bond,  or  to  di-fluorinated by-products  when only mono-fluorination was intended.[6]  We 
anticipated that adding 2 equivalents of NFSI would encourage the desired amino-difluorination.
Initial investigations began by modifying our conditions for the β-fluoroamine analogues;[5] 
adding  2  equivalents  of  NFSI  instead  of  1  equivalent  provided  17%  yield  of  the  β,β-














1)  (i) 1.32 (20 mol %)










Table 4.1: Initial Attempts at Enantioselective Amino-difluorinations
                                   Entry          temp.b          timeb          yieldc 4.5
   1                rt/rt           1d/2d            17
a Reaction conditions: (1) t-BuOMe (0.4 mL, 0.625 M), 2.18 (1.2 equiv), catalyst 1.32 (0.05 mmol, 20 mol %), 4.4 
(0.25 mmol, 1 equiv), rt, time; (2) t-BuOMe (0.6 mL, 0.25 M), NFSI (0.50 mmol, 2 equiv), temp, time. (3) NaBH4. 
bAmination/fluorination. c 4.5, after chromatography.
4.2.2 Solvent Screening
Aiming to improve this modest yield, solvent screens were undertaken for both the amination 
and fluorination steps individually. Although our β-fluoroamine organocascade necessitated t-
BuOMe as solvent for high enantioselectivity in the α-fluorination step, this was no longer a 
concern for the α,α-difluorination. We therefore felt a range of solvents should be explored, first 
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for  the  amination  component  of  the  cascade  (Table  4.2),  followed  by  the  difluorination 
component (Table 4.3).
entry          solvent          temp. (oC)          timeb          yieldc 4.6
1 rt 6h 67






























CHCl3 rt 1d 53
t-BuOMe rt 1d 56
t-BuOMe rt 2d 63
THF 4d 40
a Reaction conditions: 1) 0.25 mmol scale with 4.4 (1 equiv), 2.18 (1.2 equiv), solvent (0.625 M), catalyst 1.32 (20 
mol %), time, temp; (2) NaBH4. b consumption of 4.4 (monitored by 1H NMR). c 4.6, after chromatography.
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entry solvent time yield
1 CHCl3 2d 0c
2
3
















Table 4.3: Fluorination Solvent Screena
1d 0c



























12 t-BuOMe 2d 59b
a Reaction conditions: 0.25 mmol scale with solvent (0.25M), 4.6 (0.25 mmol), catalyst 1.32 (20 mol %), NFSI (2 
equiv), time. b 4.5, after chromatography. c difluoro-amino alcohol as percentage of product mixture, observed by 1H 
NMR. 
These experiments revealed that  although the amination was faster  in CHCl3  (Table 4.2, 
entries 1-3), the fluorination step did not tolerate chlorinated solvents (Table 4.3, entries 1-2). A 
variety of solvents and solvent combinations revealed that only ethers enabled difluorination in 
appreciable yields (entries 3, 4, 6, 12), with t-BuOMe proving the best (entry 12, 59%). Since the 
amination gave moderate to good yields in t-BuOMe (Table 4.2, entries 4, 5), albeit with longer 
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reaction times, (1-2d vs. 6h for CHCl3), t-BuOMe was chosen as the best solvent to optimize the 
organocascade.
4.2.3 Catalyst Screen for Difluorination
A few  key  observations  were  then  made  while  1H  NMR  monitoring  of  the  individual 
components of the cascade reaction. First, a monitoring of the aza-Michael component of the 
cascade revealed what should have been a singlet TMS-ether signal of the catalyst being split 
into multiple peaks. Second, an intermediate aminal species was seen to appear during the aza-
Michael step, but was not being fully consumed during the difluorination step of the cascade, 
possibly  indicating  a  ‘resting’ state  of  the  catalyst.  However,  no  such  aminal  species  was 
observed during difluorination of the isolated β-amino aldehyde. Together, these observations 
suggested  that  either,  (1)  the  TMS-ether  was  being  cleaved  from  the  catalyst,  thereby 
deactivating the catalyst, or (2) the catalyst was being otherwise deactivated, possibly by an off-
cycle species (e.g., aminal) hypothesized to be causing the multitude of silyl-ether peaks. 
Hoping  to  rectify  this  problem,  two  observations  were  utilized  for  the  following 
optimization: first, that the amination was favored in chloroform (Table 4.2), and second, that the 
difluorination need not  be enantioselective (no stereocenter  is  formed).  These clues  led to  a 
screen of racemic catalysts in chlorinated solvents, and solvent mixtures, for the fluorination step 
(Table 4.4). Since the MacMillan imidazolidinone organocatalysts were known to effect both β-
amination and (mono)-α-fluorination of  aldehydes in  chlorinated solvents,  a  variety of  these 
catalysts  were  screened  (entries  2-9).4b  However,  these  catalysts  were  not  effective  for  the 
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difluorination, giving lower yields (entries 2,6,8), or gave only the mono-fluorinated intermediate 
(entries  3-5,  7,  9).  Pyrrolidine  and  DL-proline  were  also  screened  (entries  10-14),  but  no 
fluorinated  product  was  observed.  However,  the  racemic  Hayashi-Jørgensen  catalyst  1.32r 
appeared optimal (entry 1, 78% yield), at least for the isolated difluorination. 





















































































































a Reaction conditions: 1) i. 0.25 mmol scale with solvent (1.0 mL, 0.25 M), 4.6 (0.25 mmol, 1 equiv); ii. NFSI (2 
equiv),  catalyst,  time;   b  (0.20  M)  c  Monitored  by  1H-NMR  for  consumption  of  both  SM  and  mono-fluoro 
intermediate. d yield of ‘0’ indicates no difluorinated product, but observation of only starting β-amino aldehyde 4.6, 
or mono-fluorinated intermediates by 1H NMR. e 4.5, after chromatography. 
Pleased with the good yield achieved for the difluorination using racemic catalyst 1.32r, but 
puzzled about why both pyrrolidine and racemic D,L-proline failed in the difluorination step, we 
reflected on the putative, enamine-catalyzed mechanism of the difluorination. In order to test the 
general hypothesis that the desired difluorination was indeed operating via enamine-catalysis (as 
opposed to transfer fluorination, or via base-catalyzed enol intermediates), 2-fluorotridecanal was 
subjected to difluorination conditions, but in the absence of an enamine catalyst. After 20h, this 
reaction showed no evidence of difluorination. Additionally, in the presence of DBU (1 equiv), 
the  same  2-fluorotridecanal  showed  only  traces  of  difluorinated  product  (again,  after  20h.) 
Together, these results indicate that the desired, gem-difluorination likely proceeds via sequential 
enamine-catalyzed α-fluorinations, not by base-catalysis or transfer fluorination (as would have 
been indicated by DBU-facilitated gem-difluorinations.) 
Additionally,  concerning  the  steric  bulk  of  catalyst  1.32  and  how  it  might  affect  the 
difluorination, we considered the possibility that mono-fluoro enamine intermediate 2.33e was 
mismatched with chiral catalyst 1.32, causing an unproductive resting state of the catalyst. To 
test this hypothesis, the corresponding α-fluoro-β-amino aldehyde was purified (as a 2:1 syn/anti 
diastereomeric mixture) and resubmitted to the second fluorination using chiral catalyst 1.32. 




















minor diastereomer (i.e., ‘matched’ for catalyst 1.32)  was transformed into the corresponding 
difluorinated aldehyde within 2min, while none of the major diastereomer (i.e., ‘mismatched’ for 
1.32)  was  transformed (as  indicated  by  1H NMR spectroscopy.)  At  the  same time,  the  (R)-
enantiomer  of  catalyst  1.32  (i.e.,  derived  from  D-proline)  converted  ~25%  of  the  major 
diastereomer, but none of the minor diastereomer. This trend continued throughout monitoring by 
1H NMR spectroscopy over 24h. In the light of these results, racemic 1.32r (10 mol%) was used 
in place of 1.32 for the fluorination step, further improving yield (Table 4.5, entry 6). Increasing 
the amount of 1.32r (up to 20 mol%) increased the yield of desired product 4.# (Table 4.5, entry 
7). These results provided confirmation that the mono-fluoro product of the first α-fluorination 
was mismatched for a second enamine-formation with catalyst 1.32. As such, the simple addition 
of racemic 1.32r during the difluorination understandably provided superior yields over other 
methods assessed.
As  a  result  of  independently  optimizing  both  amination  and  difluorination  steps,  and  of 
identifying t-BuOMe as the best solvent among those tested, optimization of the one-pot reaction 
was undertaken (Table 4.5). Since the combined best yields for the amination and fluorination 
(63% x 78% = 49%) was higher than for the overall cascade yield (17%), improvement of the 
cascade yield should be possible. Further optimization of the cascade was therefore undertaken, 
using t-BuOMe as solvent. Reaction concentration was considered a simple factor affecting the 
difluorination step, especially since NFSI (and the sulfonimide by-product) was poorly solvated 
in  t-BuOMe.  However,  only  marginal  improvements  over  the  initial  yield  were  seen  with 
concentrations ranging from 0.625 M – 0.100 M (Table 4.5, entries 1 vs. 2, 3). Next, due to the 
(aforementioned) possible inactivation of the organocatalyst during the amination step, adding 
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fresh catalyst after the amination was investigated. This modification demonstrated considerable 
improvement in overall  yield (entries 1 vs.  4,  5).  A still  larger improvement was seen when 
racemic  1.32r  was  added  during  the  fluorination  step  (entry  6,  39%).  The  most  sterically 
hindered Hayashi-Jørgensen catalyst, 4.12, gave a much-reduced yield (entry 7). 



























1)  (i) t-BuOMe, 
        1st catalyst
    (ii)  t-BuOMe, NFSI, 










entry 2nd catalyst tempb timec yieldd
1 -- rt 1d/2d 17
2e -- rt 1d/2d 22
3f -- rt 18h/3d 23
4 1.32 (10 mol%) rt 1d/2d 30
5g 1.32 (20 mol%) rt 1d/2d 36
6 1.32r (10 mol%) rt 1d/2d 39
7 4.12 (10 mol%) rt 1d/14h 18
a Reaction conditions: (i) 0.25 mmol scale with t-BuOMe (0.4 mL, 0.625 M), 2.18 (1.2 equiv), 1.32 (20 mol %), 4.4 
(0.25 mmol, 1 equiv), rt, time; (ii) t-BuOMe (0.6 mL, 0.25 M), NFSI (2 equiv), 2nd cat. (20 mol %), temp, time; b 
temp for fluorination. c reaction time for amination/fluorination. d yield for isolated 4.5 after chromatography. e 0.1 
M. f 0.625M. g 2-step addition (24h apart) of both NFSI (2 x 1 equiv) and 1.32 (10 mol% x 2) during difluorination 
step.
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4.2.4 Optimization of Temperature, NFSI Equivalents, Additives
With improved, although still modest, overall yields (39%, albeit over 3 steps), a range of 
small  adjustments  to  reaction  time,  temperature,  and  equivalents  of  both  amination  reagent 
(2.18 ) and NFSI were assessed, all-the-while using increased amounts of catalyst 1.32r (20 mol
%) for the difluorination (Table 4.6, all entries). Low temperature fluorination was investigated 
in an effort to suppress any potential, unwanted side-reactions. This resulted in longer reaction 
time, but failed to improve yield (Table 4.6, entry 2). Varying the equivalents of NFSI, also in an 
effort  to  inhibit  possible  side-reactions,  was  not  productive  (entries  4,  5).  Finally,  using  2 
equivalents of amine nucleophile 2.18, 2 equivalents of NFSI, and three days total reaction time 
gave an optimal yield of 54% (entry 8). 
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(1) i. t-BuOMe, (1.32, 20 mol%),
     ii. t-BuOMe, NFSI, 

















entry NFSI (equiv) timeb yieldc
1 2 1d/1d 35
2d 2 2d/3d 35
3 3 2d/2d 20
4 3 2d/1d 31
5 1.5 1d/2d 31
6e 1.5 1d/2d 42
7 2 2d/2d 52
8e 2 1d/2d 54
a Reaction conditions: 1) (i) 0.25 mmol scale with t-BuOMe (0.4 mL, 0.625 M), 2.18 (1.2 equiv), 1.32 (20 mol %), 
4.4 (0.25 mmol, 1 equiv), rt, time; (ii) t-BuOMe (0.6 mL, 0.25M), NFSI (equiv.), 1.32r (20 mol %), rt, time; b 
amination/fluorination. c 4.5, after chromatography. d 0oC fluorination. e 2.18 (2 equiv).
With an eye still on improving the overall yield, a final optimization was undertaken to study 
the effect of additives (Table 4.7). The addition of water (0.5 equiv) during the fluorination was 
evaluated based on the suspicion that  hydrates  of  the α,α-difluoro aldehyde were forming.[8] 
Since water is part of the catalytic cycle (e.g., via reversible iminium formation) we felt that 
additional water might help to sequester the product difluoroaldehyde as the hydrate, leaving the 
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stoichiometric amount of water to participate in the catalytic cycle, thereby improving overall 
yield. This however provided no benefit (Table 4.7,  entry 1). The addition of Brønsted acids 
(benzoic  and  acetic  acid),  additives  known  to  increase  the  rate  of  catalyst  turnover,  were 
evaluated, and showed increased speed of amination but had no effect on fluorination, nor did 
they improve the overall yield (Table 4.7, entries 2-7).











(1) i. t-BuOMe, (1.32, 20 mol%),
     ii. t-BuOMe, NFSI, 

















entry additives, conditions timeb yieldc
1d (ii) H2O (0.5 eq) 1d/2d 36
2e 0.625M, BzOH (20 mol%) 2.5h/1d 24
3e 0.625M, BzOH (20 mol%) 2.5h/2d 24
4e 0.25M, BzOH (20 mol%) 1d/1d 20
5e 0.625M, AcOH (20 mol%) 4h/1d 45
6e 0.625M, AcOH (20 mol%) 4h/2d 44
7e 0.25M, AcOH (20 mol%) 1d/2d 39
a Reaction conditions: (1) (i) 0.25 mmol scale with t-BuOMe (0.4 mL, 0.625 M), 2.18 (2 equiv), c1 (20 mol %), 4.4 
(0.25 mmol, 1 equiv), rt, time; (ii) t-BuOMe (0.6 mL, 0.25 M), NFSI (equiv), 1.32 (20 mol %), rt, time; (2) NaBH4. 




With optimized conditions in hand (Table 4.6, entry 8), a substrate scope was performed to 
demonstrate the cascade’s compatibility with a range of aliphatic enals. Aromatic and alkenyl 
groups spaced at least two carbons from the reactive enal functionality were compatible (Table 
4.8).
entry               2.34                      R                     yield 13 (%)b-c      ee 13 (%)d
1 2.34a n-Bu 54 (81) 91
2 2.34b Et 57 (83) 90
3 2.34c n-Pr 52 (80) 98
4 2.34d C9H19 49 (79) 92
5e 2.34d C9H19 49 (79) 92
6 2.34e CH2Bn 43 (75) 93
7 2.34f i-Bu 49 (79) 88
8 2.34g i-Pr 40 (73) 90
9 2.34h (CH2)3CHCH2 47 (78) 91
10 2.34i CH2OBn 44 (76) 92
11 2.34j (CH2)7CO2Me 47 (78) 90
12f 2.34k C9H19 54g (81) 89h









(1) (i) t-BuOMe, (1.32, 20 mol%),
     (ii) t-BuOMe, NFSI, 





















a Reaction conditions: (1) (i) 1.33 (0.25 mmol), 2.18 (0.5 mmol), 1.32 (0.05 mmol), t-BuOMe (0.4 mL), room temp., 
1d; (ii)  NFSI (0.5 mmol),  1.32r  (0.05 mmol),  t-BuOMe (0.6 mL), room temp., 2–3 d; (2) NaBH4  (2.5 equiv.), 
CH2Cl2/EtOH (2:1), room temp. b Isolated yield. c The number in parentheses corresponds to the average yield per 
step in the three-step sequence. d Determined by chiral-phase HPLC of the alcohol. e Reaction run on a 2.5 mmol 
scale. f BnONHCbz used instead of 2.18. g Yield determined by 1H NMR spectroscopy using an internal standard. h 
ee of ester 4.13 (Scheme 4.3).
4.2.6 Synthesis of Rhodopeptin Analogue Precursor
With  a  substrate  scope  providing  yields  (40-57%)  and  ee  values  (88-98%  ee)  roughly 
corresponding to those from reaction optimization (54% yield, 91% ee), a capstone substrate was 
pursued to demonstrate the utility of the organocascade. An anti-fungal candidate containing an 
aliphatic  difluoroamine  moiety  was  chosen  for  its  prospective  compatibility  with  this  new 
reaction manifold (Figure 2.4, Rhodopeptin analogue). Attaining this material has been plagued 
by a low-yielding,  non-catalytic racemic method necessitating chromatographic separation of 
diastereomer 13-steps into the full synthesis.[2] Demonstrating a catalytic, highly enantioselective 
approach to provide precursor 4.14 in fewer steps than the current 8-step method would be a 









































H3C H3C H3C8 8 8
(Method?)
Scheme 4.3: Proposed Synthesis of Rhodopeptin Analogue Precursor
Conditions were found to oxidize the organocascade product alcohol 2.34d to an intermediate 
carboxylic acid (TPAP/NMO/H2O, quantitative)[9] followed by esterification (AcCl/MeOH, 98%)
[10] to give the protected amino acid methyl ester 4.13. Difficulties arose, however, with attempts 
to deprotect the amine to give the β-amino acid methyl ester 4.14. While CBz removal proved 
routine (hydrogenation over Pd/C), cleavage of the N-O bond was known to be challenging from 
prior unsuccessful attempts with a similar, mono-fluorinated substrate.[11] 
Attempts  at  one-step  cleavage  of  both  N-CBz and  N-OMe under  various  hydrogenation 
conditions  were  not  successful.  Further  efforts  at  reductive  N-O  bond  cleavage,  including 
Mo(CO)6,,[12]  Zn/AcOH,[12]  TiCl3/H2O,[13]  and SmI2[14] were unfruitful.  Literature reports of N-O 
cleavage using SmI2 seemed promising,14  particularly a mention that  N-TFA derivatives were 
more responsive to N-O cleavage. To our great satisfaction, exchanging the N-CBz protecting 
group  for  N-TFA[15],  followed  by  treatment  with  SmI2[14]  rapidly  cleaved  the  N-O  bond  in 
quantitative  yield  (4.13b  -->  4.13c).  However,  subsequent  attempts  to  remove  the  N-TFA, 
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including  K2CO3/MeOH,[16]  NaOMe/MeOH  (reflux),[17]  and  MeOH/HCl  (reflux)[18]  were  all 





















































































































Scheme 4.4: N-O Bond Cleavage Attempts
At this point, we considered using a different nucleophile for the cascade that might ease the 
N-O cleavage, preferably without needing N-TFA protection. To this end, the organocascade was 
run using a nucleophile with N-OBn instead of N-OMe (Scheme 4.5),[19] followed by preparation 













Scheme 4.5: Preparation of Alternative Aza-Michael Nucleophile
We  especially  hoped  that  both  the  N-CBz  and  N-OBn  groups  would  be  sensitive  to 
hydrogenation for simultaneous cleavage. To our delight, hydrogenation conditions were found 



















Scheme 4.6: Hydrogenation to Free Amino Acid Ester
4.3 Conclusions
In  conclusion,  the  key  result  from  this  work  has  been  the  development  of  a  novel, 
organocatalyzed cascade reaction for the enantioselective amino-difluorination of aliphatic enals, 
providing  aliphatic  β,β-difluoroamines  in  good  yields  with  excellent  enantioselectivities.  To 
demonstrate the utility of this reaction, an improved method was devised to furnish an important 
synthetic  intermediate  towards  a  potent  anti-fungal  drug  containing  the  β,β-difluoroamine 
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moiety. Generally, this research underscores the utility and versatility of the Hayashi-Jørgensen 
organocatalysts. 
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Chapter 5.
Accessing Medicinally-Relevant Tetrahydrofuran Scaffolds via 
Organocascade Reactions
5.1 Introduction 
Transition-metal photoredox catalysis and iminium organocatalysis are two important and 
mechanistically distinct fields of chemical technology (as reviewed in Chapter 2.)  For example, 
the stereoselective α,β-functionalization of enones has be achieved using both organocatalysis[1a] 











































Under  the  proper  conditions,  combining  organocatalysis  with  photoredox  catalysis 
(organophotoredox catalysis) has also been shown capable of α,β-functionalization of enals in 


















Scheme 5.2: Organophotoredox α,β-Functionalization of Enals
1.33
5.4
Thus  far,  however,  organophotocatalytic  reactions  have  largely  focused  on  the  SOMO 
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Scheme 5.3: Organophotocatalytic Enamine-SOMO Activation
1.46
 Currently missing from the organophotocatalytic methodology is iminium-activation of an 
enal, followed by photoredox-generated β-enamine neutral radical. Such an intermediate, given 
an appropriate SOMO-philic partner, may allow access to β-functionalized aldehydes by radical 
coupling at the β-position. Precedent for a similar, enol-derived neutral radicals exists, albeit 
only via Brønsted acid activation (Scheme 5.4).[4]  These conditions provide good yields and 
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diastereoselectivity for the 5-exo-trig cyclized products, but enantioselectivity was not reported. 
Interestingly,  Lewis  acid  additives  provided  different  products,  through  a  [2+2]  cyclization 
mechanism (Scheme 5.4, path A vs path B).





Acid additive (5 equiv.)
MeCN (0.05M),
visible light, 2.5hrs




































If it can be shown that iminium-activation of an enal (as opposed to Brønsted or Lewis acid 
activation) provides similar β-SOMO reactivity, a new precedent would be set for expanding the 
utility of organophotocatalytic reactions, including the possibility for enantioselectivity. In this 
line of inquiry,  a corresponding starting enal was constructed (Scheme 5.5,  structure 5.6)  to 
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potentiate  iminium-activation  using  an  appropriate  20  amino-catalyst  in  conjunction  with 
photoredox catalysis.









a Hypothecized conditions include 2o amine as iminium activator
Prior to discussing experimental design and optimization, the following mechanistic pathway 
(Scheme 5.6) is hypothesized for the iminium-activated (here using pyrrolidine), photoredox-
catalyzed, reductive cyclization (Scheme 5.5) to be presented herein. Starting enal (5.5), together 
















































a) Red arrows indicate single-electron transfers
Ru2+
Ru+
Single-electron transfer from active reductant Ru(bpy)3+ to the β-position of iminium 5.5i can 
give rise to neutral,  stabilized enamine radical 5.5e,  which would then be poised to undergo 
intramolecular  5-exo-trig  radical  cyclization with  the  β-position of  neighboring ethyl  enone. 
Cyclized radical intermediate 5.5c may then be quenched by hydrogen atom transfer from the 
DIPEA radical cation 5.7c, followed by hydrolysis of pyrrolidine to give final product aldehyde 
5.6.  As  pyrrolidine  has  no  chiral  center,  this  hypothetical  mechanism  represents  a  racemic 
process, but is expected to exhibit some diastereoselectivity.[4b] 
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5.2 Results And Discussion
Reaction design and optimization began by adapting Yoon’s conditions (Scheme 5.4, Path B)
[4a]  to  enal  substrate  5.5  and a  range  of  additives  chosen  to  probe  iminium-activation  under 
photoredox conditions (Tables 5.1, 5.2, 5.3). These additives included Bronsted acids, hydrogen-
bond donors,  and  various  20  amines  as  iminium-promotors.  Initially,  an  excess  of  iminium-
promotors (5 equiv) was used. This was due to Yoon using large excesses of DIPEA (10 equiv), 
and  HCO2H  (5  equiv)  relative  to  starting  enone  (1.40).  This,  and  the  high  dilution  of  the 
conditions ([0.05] in MeCN, before liquid additives) meant the intermolecular reactions required 
for iminium-formation would be favored by an excess of 20 amine. Furthermore, unsure if the 2o 
amine would be consumed in the photoredox cycle (e.g., as is DIPEA: Scheme 5.6, Structures 
5.7  -->  5.8  +  5.9),  its  excess  would  maximize  the  likelihood  of  iminium-activation  and 
subsequent product formation. 
5.2.1 Initial Results
Results from initial experiments using pyrrolidine as iminium-promotor (Table 5.1) showed 
freshly distilled pyrrolidine to give better yields (up to 34%) of cyclized product 5.6 (entries 5-8) 
than pyrrolidine that was not distilled immediately prior to use. This was possibly due to the 
presence of water in the highly hygroscopic pyrrolidine. However, it  was unclear how water 
might have such a strong effect on the reaction, especially when the Ru(bpy)3Cl2 photocatalyst is 
supplied as a hydrated (hexahydrate) complex. Higher loadings of pyrrolidine gave higher yields 
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in lesser  time (entries  5-8).  However,  higher concentrations of  pyrrolidine led to significant, 
unidentified by-product formation. Less pyrrolidine (0.5 equiv, entries 7-8) gave almost no by-
products, but yields were lower and reaction times were longer. Reactions run in the absence of 
pyrrolidine (entry 1) gave no product, which may indicate the necessity of an iminium-promotor. 
Curious to know if a Brønsted acid would also promote the cyclization, formic acid was used 
(entry 2, 22%) in place of pyrrolidine, which produced a yield similar to that using pyrrolidine 
(entry 2, 24%). 








a Reactions conducted using starting enal 5.5 (0.25 mmol, 1 equiv), Ru(bpy)3Cl2 (2.5 mol%), additive (equiv) and 
DIPEA (10 equiv) in MeCN (0.05M) and irradiated for the time indicated using a 1400 lumen CFL bulb, followed 
by filtering through 3” of silica (100% EtOAc, 125mL) and concentrating for yield determination. b Yields (and 
unreacted SM) were determined on crude reaction mixtures using 1H NMR with cyclohexene (1 equiv) as internal 
standard.
From  these  data,  it  was  apparent  that  at  least  two  distinct  methods  of  activation  were 





















































other  means  (e.g.,  hydrogen-bonding),  known hydrogen-bond  donors  (diisopropylamine,  and 
pyrrolidinone) were used in place of pyrrolidine (Table 5.2, entries 1, 2). As no desired product 
was observed with the inclusion of these hydrogen-bond donors, hydrogen-bonding activation 
appeared not to be a productive pathway. Additionally, in order to probe the reactivity of the 
suspected iminium-activation, a competitive nucleophile, dimethylmalonate, (1 equiv) was used 
in conjunction with pyrrolidine as iminium-promotor (Table 5.2, entry 3). If iminium-activation 
was indeed occurring, then the presence of dimethylmalonate,  along with excess amine base 
(DIPEA, 10 equiv), could reasonably be predicted to interrupt the desired reductive cyclization, 
most likely via iminium-activated conjugate addition reactions.[5] Indeed, when this reaction was 
run  (entry  3)  a  complex  mixture  of  by-products  was  observed.  Without  significant  cyclized 
product observed, this seemed to indicate some iminium-activation.











a  Reactions conducted using starting enal 5.5 (0.25 mmol, 1 equiv), Ru(bpy)3Cl2 (2.5 mol%), additive (equiv), and 



































through 3” of silica (100% EtOAc, 125mL) and concentrating for yield determination. b Yields (and unreacted SM)  
were determined on crude reaction mixtures using 1H NMR with cyclohexene (1 equiv) as internal standard.
Although no single  experiment  in  Table  5.2  decisively  indicated  iminium-activation,  the 
combination of 1) failed hydrogen-bonding activation, 2) successful reactions using pyrrolidine 
as additive, 3) the complete lack of reactivity in the absence of pyrrolidine, and 4) the multiple 
by-products observed with the malonate competitive nucleophile, together allows for increased 
confidence in concluding this process was likely an iminium-activated, photocatalytic, reductive 
cyclization.
With these encouraging results,  we were next  curious to explore the possibility of  using 
enantioselective organocatalysts for iminium-activation (Table 5.3). To our great surprise, none 
of  the  typical  catalysts  used  for  iminium  organocatalysis  gave  observable  cyclized  product 
(entries 1-6), even when 5 equivalents of the chiral organocatalysts were used. Not surprisingly, 
however, those organocatalysts used as their ammonium salts,  did provide yields of cyclized 
product, an observation that can be rationalized by the alternative Brønsted acid activation modes 
(compare entry 8 vs 9 thru 11) observed by Yoon, et. al.[4]
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a Reactions were conducted on 0.125 mmol scale in MeCN [0.05],  with iminium promoter (equiv),  DIPEA (10 
















































































































125mL) and concentrating for yield determination. b Yields (and unreacted SM) were determined on crude reaction 
mixtures using 1H NMR with cyclohexene (1 equiv) as internal standard.
Although  these  results  provided  some  initial  discouragement  for  achieving  an 
enantioselective, organophotoredox-catalyzed reaction manifold, these studies nevertheless seem 
to indicate control over a racemic process, which could yet strengthen the case for pursuing a 
chiral version of the same. Specifically, if a racemic version can be well-understood, it may help 
to  clarify  factors  currently  limiting  the  development  of  enantioselective  iminium 
organophotoredox catalysts. Of particular interest for future, prochiral substrates would be the 
construction  of  chiral,  medicinally-relevant,  tetrahydrofuran  and  tetrahydropyran  scaffolds, 
valuable components of bio-active small molecules.[6]
5.2.2 Optimization of Racemic Conditions
Chief among the suspected background reactions targeted for reaction optimization was the 
mechanistic  fate  of  the  hydrogen-atom  donor,  N,N-diisopropylethylamine  (DIPEA.)  It  had 
previously been observed during 1H NMR monitoring of similar photoredox chemistries that as 
DIPEA was consumed, acetaldehyde arises in a dependent manner.[7] The generation of such a 
reactive aldehyde in the presence of 20 amines intended for iminium activation of enals was a 
concern during our initial reaction planning. Specifically, our concerns were that if acetaldehyde 
were to build up to significant amounts (even greater than enal substrate 5.5), its reactivity would 
likely result in one of several in either the consumption of those 20 amines intended for enal 
substrate  activation.  With  this  concern,  a  literature  survey  of  alternative  hydrogen-transfer 
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reagents revealed the possibility of constructing a similar, but more hindered, 30 amine for the 












Scheme 5.7: Synthesis of Alternative, Hindered H-atom Donor
 We  hypothesized  this  increased  steric  bulk  would  reduce  rates  of  two  suspected  (and 
unwanted) decomposition pathways that are known for DIPEA (e.g., Scheme 5.6, structures 5.7 
--> 5.10 + 5.9).[8b] These decomposition pathways, hydrolysis of iminium 5.7i (Figure 5.1) into 
diisopropylamine (5.10) and acetaldehyde (5.9), would be mirrored for DiPiBA, generating the 
corresponding (and less reactive) aldehyde, isobutyraldehyde, instead of acetaldehyde, thereby 
































However, while this newly synthesized DiPiBA was soon to be used in place of DIPEA, it 
was  concurrently  determined  that  iminium-promotor  pyrrolidine  was  causing  problems  with 
yield reproducibility, likely due to its high nucleophilicity.[9] Therefore, before an evaluation of 
DiPiBA as a hydrogen donor, we first investigated alternative iminium-promotors (Table 5.4), 
revealing  morpholine  to  be  best  among  the  secondary  amines  evaluated  (entry  2),  with 
significantly  less  background reactivity  than  pyrrolidine  (entry  1.)  In  order  to  acquire  some 
confidence  that  morpholine  was  not  activating  starting  enal  5.5  via  hydrogen-bonding  (but 
instead via iminium formation), a control reaction was performed using surrogate hydrogen-bond 
donor 3-morpholinone instead of morpholine (entry 3). Indeed, this reaction gave only 7% yield 
after extended reaction (irradiation) time (20 hours.)
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a Reactions were conducted on 0.125 mmol scale in MeCN [0.05], with iminium promoter (1 equiv), DIPIBA (10 
equiv),  Ru(bpy)3Cl2 (2.5 mol%) and irradiated (time),  followed by filtering through 3” of  silica (100% EtOAc, 
125mL) and concentrating for yield determination. b Yields (and unreacted SM)    were determined on crude reaction 
mixtures using 1H NMR with cyclohexene (1 equiv) as internal standard.
Pleased by reliably higher yields using morpholine in place of pyrrolidine, an evaluation of 
hydrogen donors was then performed, revealing the more sterically hindered DiPiBA to provide 
cleaner overall reactions, with less by-products and a higher yield (34%) of desired, cyclized 
product 5.6 (Table 5.5, entry 3). DABCO was also evaluated, but it higher nucleophilicity was 
likely the cause of minimal cyclized product formation (6%, entry 2).









































a Reactions were conducted on 0.125 mmol scale in MeCN [0.05], with morpholine (1 equiv), H-atom donor (10 
equiv),  Ru(bpy)3Cl2 (2.5 mol%) and irradiated (time),  followed by filtering through 3” of  silica (100% EtOAc, 
125mL) and concentrating for yield determination. b Yields (and unreacted SM)   were determined on crude reaction 
mixtures using 1H NMR with cyclohexene (1 equiv) as internal standard.
Given  an  optimized  choice  of  both  hydrogen  donor  (DiPiBA)  and  20  amine  iminium-
promotor (morpholine), a more extensive investigation of reaction conditions was undertaken. A 
solvent screen was performed (Table 5.6), revealing MeCN to be much preferred over DMSO, 











Table 5.6: Solvent Screena
a Unless noted otherwise, reactions were conducted on 0.125 mmol scale at [0.1] in (solvent), DiPiBA (5 equiv), 
Ru(bpy)3Cl2 (2.5 mol%), with morpholine (0.5 equiv added via syringe-pump over 4h, irradiated for 6h, followed by 
filtering  through  3”  of  silica  (100% EtOAc,  125mL)  and  concentrating  for  yield  determination.  b  Yields  (and 
unreacted SM)   were determined on crude reaction mixtures using 1H NMR with cyclohexene (1 equiv) as internal 
standard.
Continuing with MeCN as solvent, and curious whether an excess of hydrogen donor was 
necessary, a survey of different equivalents of DiPiBA was performed (Table 5.7.) This study 
demonstrated  a  correlation  between  equivalents  of  DiPiBA and  increases  in  yield,  with  10 










































a Reactions were conducted on 0.125 mmol scale (in enal 5.5) in MeCN [0.1], with morpholine (0.5 equiv), DiPiBA 
(equiv), Ru(bpy)3Cl2  (2.5 mol%) and irradiated (time), followed by filtering through 3” of silica (100% EtOAc, 
125mL) and concentrating for yield determination. b Yields (and unreacted SM)   were determined on crude reaction 
mixtures using 1H NMR with cyclohexene (1 equiv) as internal standard.
Next, an investigation into reaction concentration (Table 5.8) showed more dilute conditions 
to give the best overall results, despite the intermolecular iminium formation required for our 
hypothesized  reaction  mechanism  (Scheme  5.....  Interestingly,  although  much  reduced 
concentration  ([0.025],  entry  1)  gave  a  superior  yield  of  desired  cyclization  product  (52%), 
background reactivity resulted in 40% by-products, observed as a complex mixture by 1H NMR. 






















































a Reactions were conducted on 0.125 mmol scale in MeCN [0.05], with DiPiBA (10 equiv), Ru(bpy)3Cl2 (2.5 mol%), 
and morpholine (1 equiv) added neat at the beginning, followed by irradiation (time), and quenching through 3” of 
silica (100% EtOAc, 125mL) before concentration for yield determination. b  Yields (and unreacted SM)   were 
determined on crude reaction mixtures using 1H NMR with cyclohexene (1 equiv) as internal standard.
Next,  equivalents of morpholine was investigated at  different reaction (irradiation) times, 
showing a clear correlation between increased yields and stoichiometric amounts of morpholine, 






































a Reactions were conducted on 0.125 mmol scale in MeCN [0.05], with morpholine (equiv), DiPiBA (10 equiv), 
Ru(bpy)3Cl2 (2.5 mol%) and irradiated (time), followed by filtering through 3” of silica (100% EtOAc, 125mL) and 
concentrating for yield determination. b  Yields (and unreacted SM) were determined on crude reaction mixtures 
using 1H NMR with cyclohexene (1 equiv) as internal standard.
Interestingly, when lesser equivalents of morpholine were irradiated for longer times, yields 
did  not  universally  increase  but  plateaued  (entries  2-4  & 5-7).  This  seemed to  indicate  the 
reaction was stalling when <1 equiv morpholine was used, with little conversion occurring past 
5hrs of irradiation. However, this data also showed that more than 2 equivalents of morpholine 
caused  excessive  background  reactions,  with  4  equivalents  morpholine  consuming  55%  of 
starting enal, while providing only 32% desired product (entry 11.) 
In  continuing  efforts  to  identify  the  suspected  background  reactivity  responsible  for 
consuming (valuable) starting enal 5.5 by unwanted pathways, reactions were conducted at both 















































































a Reactions were conducted on 0.125 mmol scale, followed by filtering through 3” of silica (100% EtOAc, 125mL) 
and concentrating for yield determination. b  Yields (and unreacted SM) (%) were determined on crude reaction 
mixtures by 1H NMR using an internal standard. c  Morpholine (2 equiv) was added neat,  prior to irradiation. d 
Morpholine (1 equiv) was added at t=0h, then 1 equiv extra at t=12h.
Unfortunately, neither temperature changes (entries 2, 3) showed any improvement over the 
so-far best conditions (Table 5.9, entry 10; 64%.) Interestingly, when the reaction was irradiated 
for 1h, then placed in the dark for the remaining time (15h), over half of starting enal 5.5 was 
consumed via pathways not giving rise to desired cyclized product 5.5. This data revealed that 
background reactivity was likely occurring both under irradiation as well as in the dark, as a 
similar reaction (Table 5.9, entry 8) showed more starting enal remaining (39%) after 2.5h than 
did this  dark reaction after  16h.  Due to this  suspicion that  morpholine was being consumed 
during  the  reaction  (i.e.,  not  acting  catalytically),  we  decided  to  finish  optimizing  for  the 
stoichiometric (as opposed to catalytic) process, with an intention that future research might still 
benefit from the nevertheless high-yielding process. 


































a  Reactions  conducted  on  0.125  mmol  scale  (enal  5.5)  in  (degassed)  MeCN [0.05],  with  DiPiBA (10  equiv), 
Ru(bpy)3Cl2 (2.5 mol%), morpholine (2 equiv) added slowly via syringe-pump (add time), and irradiated for 16h, 
followed by filtering through 3” of silica (100% EtOAc, 125mL) and concentrating for yield determination. b Yields 
(isolated) (and % unreacted SM) were determined on crude reaction mixtures using 1H NMR with internal standard. 
c Morpholine (2 equiv) was added in two parts: 1 equiv at t = 0, and 1 equiv at t=12h.
This final optimization study revealed that a simple addition of extra morpholine at 12h (for a 
total of 2 equiv morpholine) gave slightly better results (entry 3, 75%; 65% isolated yield after 
chromatography) than did syringe-pump addition over the same time (entry 2, 70%), or addition 
over  8h  (entry  1,  68%.)  Overall,  this  reaction  optimization,  although  not  yet  facilitating  a 
catalytic  or  enantioselective  protocol,  has  increased  the  yield  of  the  racemic  products 
dramatically from an initial 18% (Table 5.1, entry 5) to 75% (65% isolated, Table 5.11, entry 3.)
5.2.3 Substrate Scope
With optimized conditions in hand, a substrate scope was undertaken to survey the versatility 













































































































a Reactions conducted on 0.125 mmol scale (enal 5.5), with morpholine (2 equiv) added at t=0h (1 equiv) and t=12h 
(1  equiv),  before  filtering  through  3”  of  silica  (100%  EtOAc,  125mL)  and  concentrating.  b  yield  (1H  NMR) 
determined  on  crude  reaction  mixtures  using  an  internal  standard.  Isolated  yields  determined  after  silica  gel 
chromatography. c d.r. (diastereomeric ratio) determined by 1H NMR. 
This  substrate  scope  shows  good  overall  yields  (42-73%,  isolated),  and  good 
diastereoselectivity (d.r. from 1:1 to 13:1), for what appears to be a novel iminium-activated, 
photoredox-catalyzed  process  for  accessing  potentially  medicinally-relevant  functionalized 
carbocycles and tetrahydrofurans.  Interestingly, after this substrate scope was finished, out of 
curiosity for any differences in reactivity possessed by the only aromatic substrate (5.14e, with 
R3 = phenyl) was again synthesized using the same process as in Table 5.12,  only this time 
without the addition of morpholine as iminium-promotor. To out surprise, full conversion  to 
cyclized product 5.14e was observed by 1H NMR spectra of the crude reaction mixture. One 
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explanation of this reactivity is that this substrate’s extended aromatic systems allow for greater 
stabilization of radical ions generated during the photoredox catalytic cycle. In order to know if 
this  is  indeed  happening,  it  may  be  useful  to  subject  aromatic  substrate  5.15e  to  cyclic 
voltammetry studies, comparing its redox potentials with those for aliphatic substrates (any or all 
substrates 5.14, excepting 5.14e), and with attention paid to any significant differences. 
5.3 Conclusions
Although  the  studies  described  herein  appeared  to  indicate  a  novel,  iminium-activated, 
photoredox-catalyzed,  reductive  cyclization  of  enals,  it  was  subsequently  determined,  via 
additional  control  studies  in  the  Brenner-Moyer  lab  (in  the  absence  of  this  author),  that 
unidentified  background  reactions  not  involving  visible-light  photoredox  catalysis  may  have 
been  responsible  for  the  observed  reductive  cyclizations  occurring  under  the  conditions 
described herein. 
Should any future understanding and/or minimization of the background reactivity reported 
herein  be  achieved,  this  author  believes  that  any  future  optimizations  could  benefit  from 
consolidating reagents commonly being used in this type of multi-component reaction.[10]  For 
example,  exploration  of  alternative  hydrogen-atom transfer  agents,  especially  those  with  the 
potential for dual-reactivity (e.g., as hydrogen-atom transfer agent and as iminium-activator in a 
single  molecule),  could  consolidate  (2  or  more)  reaction  components.  Additionally,  if  this 
(hypothetical)  multi-purpose  additive  were  chiral,  still  another  function  (enantioselectivity) 
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might be fulfilled by a single reaction component. Yet another approach to consolidation might 
be to explore alternative charge-transfer ligands for the metal-based photoredox catalyst (in place 
of 2,2’-bipyridyl ligands in Ru(bpy)2Cl2), notably those with potential to transfer chirality via 
their  excited-state  redox  reactivity,  might  potentiate  enantioselectivity  without  the  need  for 
additional, chiral iminium-promotors.[11] 
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All chemicals used were ACS Reagent grade and used as received unless otherwise noted. 1H and 
13C NMR spectra were acquired using a Bruker 400 MHz Biospin instrument (400 MHz for 1H, 
101 MHz for 13C), using CDCl3 as solvent and internal reference (δ = 7.26 for 1H, 77.0 for 13C). 
The NMR data herein use the following abbreviations: s = singlet, d = doublet, t = triplet, q = 
quartet, m = multiplet, dd = doublet of doublets, td = triplet of doublets, dt = doublet of triplets, 
ddt = doublet of doublet of triplets, br = broad signal. Enantiomeric excesses were determined 
using a Perkin Elmer Series 200 HPLC with Daicel Chiralpak AD-H (0.46 x 25 cm), Chiralpak 
OD-H (0.46 x 25 cm), and Chiralpak AS-H (0.46 x 25 cm) columns. Optical rotations were 
acquired using a Jasco P-1020 polarimeter. IR spectra were collected using a Nicolet 6700 FT-
IR. High resolution mass spectra were collected using an Agilent 6520 Q-TOF. Silica gel flash 
chromatography was carried out using Silicycle F60, 40-63 μm 60Å silica gel and with EMD 
silica 60 F254 glass TLC plates. Solvents were dried and kept air free in a solvent purification unit. 
Solvents were evaporated using a standard rotovapor and a high vacuum. All reactions were 
carried out in oven dried glassware and conducted under an argon atmosphere.
6.2 Experimental and Characterization for Chapter 3
Determination of relative and absolute configurations 
The relative and absolute configuration of Michael-Michael product 3.18m was determined via 
X-ray crystallography.
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It was established that 3.18a(α-epimer) was the C4 epimer of 3.18a(β-epimer) by subjecting 
pure  3.18a  (as  a  single  epimer)  to  catalyst  1.32  (10  mol%)  in  CF3CH2OH (0.3  M),  which 
produced  a  mixture  of  3.18a(α-epimer)  and  3.18a(β-epimer).  The  configurations  of  other 
Michael-Michael products were assigned by analogy.
Preparation of catalysts (1.32, 3.20), enals (1.33m, 1.33g, 1.33h), and β-ketoesters (7, 25)
Catalysts 1.32 and 3.20[1] were prepared from the corresponding diarylprolinols[2] using known 
procedures. Enals 1.33g and 1.33h were prepared using a known procedure.[3]  β-ketoesters of 
type 3.21 (except 3.21n, 3.21l and 3.21i, whose preparation and characterization are described 
below) were prepared according to a known literature procedure.[4]
Preparation and characterization of starting enals (1.33m, 1.33g, 1.33h)








A solution  of  4-bromobenzaldehyde  (2.41  g,  13.0  mmol)  and  triphenylphosphoranylidene 
acetaldehyde (4.75 g,  15.6 mmol)  in  toluene (103 ml)  was heated at  80oC for  16 h.  To the 
reaction  mixture  was  added  triphenylphosphoranylidene  acetaldehyde  (250  mg,  0.06  mmol 
mmol) again and the reaction mixture was further refluxed for 19 h. After the reaction mixture 
was concentrated in vacuo, the crude residue was chromatographed on silica gel eluting with 
Et2O/pet.ether  (7.5:92.5)  to give 1.33m  (1.82 g,  66%) as a yellow solid.  Characterization of 




(E)-3-(4-bromophenyl)acrylaldehyde,  Yellow  solid;  m.p.:  78-79oC;  1H  NMR  (400  MHz, 
CDCl3) δ 9.71 (d, J = 7.6 Hz, 1H), 7.57 (m, 2H), 7.43 (m, 3H), 6.70 (dd, J = 16.0, 7.6 Hz, 1H); 
13C NMR (101 MHz, CDCl3) δ 193.3, 151.1, 132.9, 132.4, 129.8, 129.1, 125.7 ppm.
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Preparation and characterization of β-ketoesters:
Most β-ketoesters were prepared according to a known literature procedure.[6] β-ketoester 3.21n 
was prepared by adapting this procedure. 
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1) To a round-bottom flask was added THF (22 mL) and diisopropylamine (844 μL 6.6 mmol) 
and cooled to  -78oC. n-BuLi (2.5M in hexanes, 6.6 mmol) was added slowly and stirred for 15 
minutes. Ethyl acetate (586 μL, 6.0 mmol) was then added dropwise and the solution stirred for 
50 minutes. Enal 1.33h (6.0 mmol) was added dropwise and stirred for 10 minutes. The reaction 
was quenched by the addition of sat. aq. NH4Cl (1.7 ml), followed by immediate transfer to a 
separatory funnel containing diethyl ether (25 ml). The mixture was extracted with diethyl ether 
(25 mL), washed with brine (2 x 25 ml) and water (2 x 25 mL), and dried over MgSO4. Removal 
of solvent yielded the hydroxyester in >99% yield. No further purification was needed before the 
oxidation with Jones’ Reagent. 
2) Jones’ Reagent was prepared by the addition of concentrated H2SO4 (1.8 mL) to CrO3 (2.0 g) 
followed by careful dilution with water to give a total volume of 15 mL. Then, Jones’ Reagent 
(9.0 mL, 9.0 mmol) was added dropwise to a stirred solution of the β-hydroxyester (6.0 mmol) in 
acetone (24 mL) at 0oC. After complete addition of the oxidizing agent, the reaction was stirred 
for  10  minutes,  when  the  absence  of  starting  material  was  determined  by  thin-layer 
chromatography. Methanol (1.5 mL) was added slowly to quench excess Jones’ Reagent. The 
reaction mixture was poured into a separatory funnel and extracted with diethyl ether (30 mL). 
The organic extracts were washed with water (3 x 20 mL) and then brine (2 x 20 mL). The 
organic layer was dried (MgSO4) and filtered and the solvent removed under reduced pressure. 
Purification of the crude product mixture was achieved by flash chromatography (silica gel, 2.5% 










(E)-ethyl  5-(2-fluorophenyl)-3-oxopent-4-enoate,  white  solid.  m.p.:  57-58oC;  IR  (thin  film, 
KBr): 2983, 1741, 1649, 1596, 1486, 1458, 1422, 1235, 1148, 1094, 1039, 969, 799, 755 cm-1; 1H 
NMR (400 MHz, CDCl3) (1:2 ratio of keto : enol) δ 11.99 – 11.94 (d, J = 1.3 Hz, 1H, enol), 7.81 
– 6.81 (m, 10H), 6.59 – 6.50 (dd, J = 16.1, 1.5 Hz, 2H), 5.21 – 5.16 (s, 1H, enol), 4.29 – 4.17 
(qd, J = 7.1, 4.6 Hz, 4H), 3.73 – 3.68 (s, 2H, keto), 1.36 – 1.24 (m, 6H); 13C NMR (101 MHz, 
CDCl3) δ  192.1, 172.8, 168.9, 167.3, 162.9, 162.4, 159.9, 137.0, 136.9, 132.4, 132.3, 130.7, 
130.6, 129.5, 129.4, 129.2, 129.1, 128.7, 128.6, 127.4, 127.4, 124.6, 124.6, 124.5, 124.4, 124.4, 
124.3, 123.5, 123.4, 116.4, 116.2, 116.2, 116.0, 92.5, 61.5, 60.3, 47.6, 14.3, 14.1 ppm; HRMS 
(ESI) calcd for C13H13F O3 [M]+ 236.0849, found 236.0860.
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β-ketoesters 3.21i and 3.21l were prepared by a modification of the same procedure.
Ar H







Ar = 1-furyl (1.33i), or
p-MeO-phenyl (1.33l)
Ar = 1-furyl (3.21i) or
p-MeO-phenyl (3.21l)
1) To a round-bottom flask was added THF (22 mL) and diisopropylamine (844 μL 6.6 mmol). 
The reaction was cooled to  -78oC. n-BuLi (2.5M in hexanes, 6.6 mmol) was added slowly and 
stirred for  15 minutes.  Ethyl  acetate  (586 μL, 6.0  mmol)  was then added dropwise and the 
solution was stirred for 50 minutes. Enal 1.33 (6.0 mmol) was added dropwise and stirred for 10 
minutes. The reaction was quenched by the addition of sat. aq. NH4Cl (1.7 ml), followed by 
immediate transfer to a separatory funnel containing diethyl ether (25 ml).  The mixture was 
extracted with diethyl ether (25 mL), washed with brine (2 x 25 ml) and water (2 x 25 mL), then 
dried over MgSO4. Removal of solvent yielded the hydroxyester in 98-100% yield. No further 
purification was typically needed before the oxidation with DMP. However, purification could be 
achieved on silica gel with 15%-25% Et2O in petroleum ether.
2) To a solution of the hydroxyester (2.0 mmol) corresponding to 9 in CH2Cl2 (55.5 mL) and 
MeCN (77.1 mL) at r.t. was added NaHCO3 (330.6 mg, 3.9 mmol) mmol). The mixture was 
cooled to  0oC and Dess-Martin  Periodinane (1  equiv)  was added.  The reaction mixture  was 
stirred at 0oC for 1 hr. TLC (10% EtOAc in pet. ether) indicated ~10% SM remaining, so the 
reaction mixture was warmed to room temperature and stirred for an additional 30 minutes. TLC 
at this point indicated all SM had been consumed. The reaction was quenched with a 1:1 solution 
(110  mL)  of  saturated  NaHCO3  and  saturated  Na2S2O3  and  was  stirred  vigorously  until  the 
organic layer  was no longer  cloudy.  The quenched reaction mixture was then poured into a 
separatory funnel. The aqueous layer was extracted with CH2Cl2 (2 x 40 mL). The organic layers 
were  combined,  dried  over  Na2SO4,  filtered  and  concentrated.  Purification  by  column 
chromatography (silica gel, 5% Et2O/petroleum ether) provided yellow solids in 53-55% yield.










(E)-ethyl 5-(furan-2-yl)-3-oxopent-4-enoate,  Yellow solid. 1H NMR (400 MHz, CDCl3) (1.4:1 
ratio of keto to enol) δ 11.92 (s, 1H, enol), 7.35 (m, 4H), 6.50 (m, 6H), 5.12 (s, 1H, enol), 4.20 
(qd, J = 7.1, 4.3 Hz, 4H), 3.62 (s, 2H, keto), 1.27 (dt, J = 10.7, 7.1 Hz, 6H); 13C NMR (101 MHz, 
CDCl3) (1.4:1 ratio of keto to enol) δ 191.4, 172.8, 168.9, 167.4, 151.8, 150.8, 145.4, 143.9, 
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143.6, 130.3, 126.9, 124.6, 123.6, 122.3, 121.2, 119.9, 116.7, 113.0, 112.7, 112.2, 112.1, 91.9, 













(E)-ethyl 5-(4-methoxyphenyl)-3-oxopent-4-enoate, Yellow solid. 1H NMR (400 MHz, CDCl3) 
(1:3.6 ratio of keto to enol) δ 12.07 – 11.98 (s, 1H, enol), 7.61 – 7.34 (m, 8H), 7.00 – 6.21 (m, 
4H), 5.15 – 5.10 (s, 1H, enol), 4.30 – 4.13 (m, 4H), 3.87 – 3.80 (s, 6H), 3.70 – 3.65 (s, 2H, keto), 



































































































































































General Procedure for synthesis of carbocycles (3.18)
To an oven-dried flask was added catalyst 1.32 (13.0 mg, 0.04 mmol), CF3CH2OH (1.33 mL), β-
ketoester 3.21 (0.4 mmol), and enal 1.33 (0.4 mmol). The reaction was allowed to stir for the 
indicated time at room temperature. The reaction mixture was concentrated and filtered through a 
plug of silica, followed by concentration again. The percent conversion of the crude reaction 
mixture was determined using an internal standard (allyl alcohol). The diastereomeric ratio was 
determined through comparison of the relative integrations of the aldehyde peaks in this 1H NMR 
spectrum. The diastereomeric mixture was then purified via column chromatography (silica gel, 
95/5, petroleum ether/Et2O, unless noted otherwise) and an isolated yield of the diastereomeric 
117
mixture was determined.was determined. Purified samples of the major diastereomer and minor 
diastereomers were obtained through further flash chromatography. In certain cases (3.18c, 3.19f 
3.18g), the major epimer of the major diastereomer was inseparable from the minor epimer of the 
major diastereomer and the epimers were characterized as a mixture. Racemic samples of the 









carboxylate, Clear oil. [α]D26 = +80.4 (c=0.60, CHCl3, 93% ee ); IR (thin film, KBr): 2957, 2928, 
2858, 1721, 1653, 1519, 1347, 1277, 1230, 1094, 1044, 854 cm-1; 1H NMR (400 MHz, CDCl3) δ 
12.56 (s, 1H), 9.83 (s, 1H), 8.17 (d, J = 8.7 Hz, 2H), 7.36 (d, J = 8.7 Hz, 2H), 4.40 (d, J = 2.7 Hz, 
1H), 4.02 (qd, J = 7.1, 1.7 Hz, 2H), 2.60 (m, 2H), 2.32 (dd, J = 18.8, 10.8 Hz, 1H), 1.95 (dd, J = 
16.3, 6.2 Hz, 1H), 1.49 (m, 2H), 1.21 (m, 4H), 0.96 (t, J = 7.1 Hz, 3H), 0.83 (dd, J = 9.1, 4.6 Hz, 
3H); 13C NMR (101 MHz, CDCl3) δ 201.5, 173.2, 171.4, 152.1, 146.7, 128.6, 123.7, 97.2, 60.7, 
56.6, 38.9, 33.0, 31.9, 30.1, 29.4, 22.5, 13.9, 13.8 ppm; the enantiomeric excess was determined 
by HPLC with an AD-H column (n-hexane: i-PrOH = 99:1), 0.1 mL/min; major enantiomer tR = 










carboxylate, Clear oil. [α]D23 = +26.2 (c=0.59, CHCl3, 94% ee ); IR (thin film, KBr): 2957, 2930, 
2860, 1722, 1655, 1621, 1520, 1347, 1278, 1221, 1156, 1109, 854, 705 cm-1;  1H NMR (400 
MHz, CDCl3) δ 12.47 (s, 1H), 9.12 (d, J = 4.4 Hz, 1H), 8.18 (d, J = 8.7 Hz, 2H), 7.31 (d, J = 8.7 
Hz, 2H), 4.33 (d, J = 5.6 Hz, 1H), 4.02 (dd, J = 12.5, 7.1 Hz, 2H), 2.82 (dd, J = 18.6, 5.7 Hz, 
1H), 2.53 (m, 1H), 2.25 (m, 2H), 1.26 (m, 6H), 1.00 (t, J = 7.1 Hz, 3H), 0.89 (t, J = 6.9 Hz, 3H); 
13C NMR (101 MHz, CDCl3) δ 204.3, 172.5, 170.9, 148.0, 147.1, 129.9, 123.5, 99.0, 60.7, 54.9, 
41.2, 33.9, 33.7, 28.2, 27.9, 22.7, 13.9, 13.8 ppm; the enantiomeric excess was determined by 
HPLC with an AS-H column (n-hexane: i-PrOH = 90:10), 0.5 mL/min; major enantiomer tR = 










carboxylate, Clear oil. [α]D25 = +59.8 (c=0.45, CHCl3, 98% ee ); IR (thin film, KBr): 2962, 2925, 
1722, 1651, 1519, 1348, 1277, 1225, 1099, 853, 736, 700 cm-1; 1H NMR (400 MHz, CDCl3) δ 
12.56 (s, 1H), 9.81 (d, J = 0.6 Hz, 1H), 8.16 (m, 2H), 7.36 (m, 2H), 4.40 (d, J = 3.8 Hz, 1H), 4.01 
(qd, J = 7.1, 2.9 Hz, 2H), 2.62 (dd, J = 18.5, 5.6 Hz, 1H), 2.53 (t, J = 3.4 Hz, 1H), 2.33 (dd, J = 
18.1, 10.0 Hz, 1H), 2.22 (dd, J = 6.8, 3.4 Hz, 1H), 1.13 (d, J = 6.9 Hz, 3H), 0.95 (t, J = 7.1 Hz, 
3H); 13C NMR (101 MHz, CDCl3) δ 201.2, 172.9, 171.4, 152.3, 146.7, 128.6, 123.6, 97.2, 60.7, 
57.9, 38.5, 34.9, 24.9, 17.4, 13.8 ppm; the enantiomeric excess was determined by HPLC with an 
AD-H column (n-hexane: i-PrOH = 99:1), 0.2 mL/min; major enantiomer tR = 38.4 min, minor 









carboxylate, Clear oil. [α]D23 = +62.9 (c=1.67, CHCl3, 95% ee );  IR (thin film, KBr): 2965, 
2933, 2877, 1721, 1652, 1519, 1348, 1275, 1222, 853, 756, 737, 701 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 12.57 (s, 1H), 9.83 (s, 1H), 8.17 (d, J = 8.8 Hz, 2H), 7.36 (d, J = 8.6 Hz, 2H), 4.41 (d, J 
= 2.7 Hz, 1H), 4.02 (qd, J = 7.1, 1.7 Hz, 2H), 2.62 (m, 2H), 2.31 (dd, J = 18.8, 10.9 Hz, 1H), 
1.87 (m, 1H), 1.54 (ddd, J = 29.7, 14.3, 6.9 Hz, 2H), 0.97 (t, J = 7.1 Hz, 3H), 0.88 (t, J = 7.4 Hz, 
3H); 13C NMR (101 MHz, CDCl3) δ 201.5, 173.2, 171.4, 152.1, 146.7, 128.6, 123.7, 97.2, 60.7, 
56.5, 38.9, 32.6, 31.8, 25.2, 13.8, 11.8 ppm; the enantiomeric excess was determined by HPLC 
with an AD-H column (n-hexane: i-PrOH = 97:3), 0.5 mL/min; major enantiomer tR = 25.8 min, 










biphenyl]-2-carboxylate, Clear oil. [α]D24 = +71.7 (c=1.71, CHCl3, >99% ee ); IR (thin film, 
KBr): 2962, 2927, 2872, 1720, 1655, 1519, 1348, 1301, 1281,1264, 1223, 1096, 1033, 854, 832 
cm-1; 1H NMR (400 MHz, CDCl3) δ 12.55 (s, 1H), 9.85 (s, 1H), 8.18 (d, J = 8.8 Hz, 2H), 7.34 (d, 
J = 8.5 Hz, 2H), 4.42 (s, 1H), 4.04 (qd, J = 7.1, 0.8 Hz, 2H), 2.76 (s, 1H), 2.66 (dd, J = 19.1, 6.1 
Hz, 1H), 2.31 (dd, J = 19.0, 12.1 Hz, 1H), 1.86 (m, 1H), 1.42 (m, 1H), 0.96 (m, 6H), 0.78 (d, J = 
6.6 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 201.7, 173.7, 171.3, 151.6, 146.8, 128.4, 123.7, 
96.6, 60.8, 54.0, 39.4, 36.9, 31.7, 31.6, 29.7, 21.1, 20.6, 13.9 ppm. the enantiomeric excess was 
determined by HPLC with an AS-H column (n-hexane:  i-PrOH = 99:1),  0.3 mL/min;  major 
enantiomer tR = 31.6 min, minor enantiomer tR = 50.4 min. HRMS (ESI) calcd for C19H22NO6 [M-









terphenyl]-4'-carboxylate,  White amorphous solid.  [α]D23  = +247.5 (c=0.93, CHCl3,  99% ee 
(18), >99% ee (epi-18)); IR (thin film, KBr): 2983, 1722, 1653, 1618, 1596, 1518, 1403, 1347, 
1259, 1217, 1065, 853, 829, 753, 700 cm-11H NMR (400 MHz, CDCl3) (10:1 mixture of 18 to its 
C4 epimer) δ 12.69 (s, 1H, 18), 12.55 (s, 1H, epi-18), 9.68 (s, 1H, 18), 8.88 (d, J = 3.8 Hz, 1H, 
epi-18), 8.28 – 8.17 (m, 4H, 18+epi-18), 7.50 - 7.04 (m, 14H, 18+epi-18), 4.66 – 4.49 (m, 2H, 
18+epi-18), 4.07 (m, 4H, 18+epi-18), 3.55 – 3.26 (m, 2H, 18+epi-18), 3.12 (m, 1H, epi-18), 3.05 
–  2.75 (m,  4H,  18+epi-18),  2.66 (dd,  J  =  19.0,  11.4  Hz,  1H,  epi-18),  1.06 –  0.93 (m,  6H, 
18+epi-18); 13C NMR (101 MHz, CDCl3) (10:1 mixture of 18 to its C4 epimer) δ 203.4 (epi-18), 
200.8, 172.5, 172.2 (epi-18), 172.1 (epi-18), 171.4, 152.1, 146.9, 140.5 (epi-18), 139.2, 130.2 
(epi-18), 129.3 (epi-18), 128.9, 128.6, 127.7 (epi-18), 127.6 (epi-18), 127.4, 127.3, 123.9, 123.6 
(epi-18), 97.1, 60.8, 58.5, 54.3 (epi-18), 41.4 (epi-18), 38.8, 37.5 (epi-18), 35.3 (epi-18), 34.3, 
31.0, 30.9 (epi-18), 13.8 ppm; the enantiomeric excess was determined by HPLC with an AS-H 
column (n-hexane: i-PrOH = 95:5), 1.0 mL/min; major diastereomer: major enantiomer tR = 27.9 
min., minor enantiomer tR = 35.9 min.; minor diastereomer: major enantiomer tR = 48.7 min., 
minor enantiomer tR = 56.1 min.  HRMS (ESI) calcd for C22H21NO6 [M-H]-  394.1291,  found: 









terphenyl]-4'-carboxylate, Clear oil. [α]D26 = +86.2 (c=2.0, CHCl3, 99% ee ); IR (thin film, 
KBr): 3060, 3027, 2907, 2829, 2732, 1722, 1652, 1621, 1495, 1452, 1403, 1370, 1351, 1292, 
1259, 1216, 1066, 1032, 831, 756, 700 cm-1; 1H NMR (400 MHz, CDCl3) (5:1 mixture of 19 to its 
C4 epimer) δ 12.68 (s, 1H, 19), 12.53 (s, 1H, epi-19), 9.72 (s, 1H, 19), 8.84 (d, J = 4.4 Hz, 1H, 
epi-19), 7.28 (m, 20H, 19 + epi-19), 4.44 (m, 2H, 19 + epi-19.), 4.08 (m, 4H, 19 + epi-19.), 3.58 
(td, J = 11.9, 6.2 Hz, 1H, epi-19), 3.43 (m, 1H, 19), 2.93 (m, 6H, 19 + epi-19), 1.01 (t, J = 7.1 
Hz, 6H, 19 + epi-19); 13C NMR (101 MHz, CDCl3) (5:1 ratio of major 19 to its C4 epimer) δ 
204.7 (epi-19), 201.9, 171.9, 171.9, 171.4 (epi-19), 144.0, 141.2 (epi-19), 140.2, 139.5 (epi-19), 
129.3  (epi-19),  129.1  (epi-19),  128.7,  128.5,  128.4  (epi-19),  127.7  (epi-19),  127.6,  127.4 
(epi-19), 127.4, 127.1 (epi-19), 127.0, 126.6, 99.9 (epi-19), 97.9, 60.5, 59.0, 54.6 (epi-19), 41.7 
(epi-19), 38.9, 37.5 (epi-19), 35.2 (epi-19), 34.1, 31.1, 13.8 ppm; the enantiomeric excess of a 
mixture of 19 and epi-19 was determined by HPLC with an AS-H column (n-hexane: i-PrOH = 
97:3), 0.5 mL/min; major diastereomer: major enantiomer tR = 14.8 min., minor enantiomer tR = 
17.8 min.; minor diastereomer: major enantiomer tR = 59.6 min., minor enantiomer tR = 28.5 min. 










terphenyl]-4'-carboxylate,  Clear  oil.  [α]D23  =  +101.3  (c=2.0,  CHCl3,  99%  ee  (20)  95%  ee 
(epi-20)); IR (thin film, KBr): 2979, 2922, 2730, 1723, 1652, 1619, 1510, 1497, 1454, 1403, 
1365, 1259, 1215, 1096, 1065, 821, 759, 699; 1H NMR (400 MHz, CDCl3) (2.5:1 ratio of 20 to 
its C4 epimer) δ 12.63 (s, 1H, 20), 12.48 (s, 1H, epi-20), 9.69 (d, J = 0.6 Hz, 1H, 20), 8.80 (d, J 
= 4.4 Hz, 1H, epi-20), 7.19 (m, 18H, 20 + epi-20), 4.37 (m, 2H, 20 + epi-20), 4.05 (m, 4H, 20 + 
epi-20), 3.46 (m, 2H, 20 + epi-20), 2.79 (m, 6H, 20 + epi-20), 2.34 (m, 6H, 20 + epi-20), 1.02 
(td, J = 7.1, 1.1 Hz, 6H, 20 + epi-20); 13C NMR (101 MHz, CDCl3) (2.5:1 ratio of 20 to its C4 
epimer) δ  204.9 (epi-20), 202.1, 172.0, 171.8, 171.5 (epi-20), 171.2 (epi-20), 141.3 (epi-20), 
140.9, 140.3, 136.6 (epi-20), 136.4 (epi-20), 136.0, 129.2, 129.1 (epi-20), 129.0 (epi-20), 128.7, 
127.7 (epi-20), 127.5, 127.4, 127.0 (epi-20), 100.1 (epi-20), 98.1, 60.5, 59.1, 54.6 (epi-20), 41.2 
(epi-20), 38.5, 37.5 (epi-20), 35.2 (epi-20), 34.1, 31.1, 21.0, 13.8 ppm; the enantiomeric excess 
of a mixture of 20 and epi-20 was determined by HPLC with an AS-H column (n-hexane: i-
PrOH =  97:3),  0.5  mL/min;  major  enantiomer  of  major  diastereomer  tR  =  14.3  min,  minor 
enantiomer  tR  =  17.9  min;  major  enantiomer  of  minor  diastereomer  tR  =  47.3  min.,  minor 










terphenyl]-4'-carboxylate,  Clear oil.  [α]D23  = +82.5 (c=2.0,  CHCl3,  98% ee );  IR (thin film, 
KBr): 2982, 2929, 2734, 1724, 1620, 1654, 1486, 1454, 1404. 1259, 1216, 1094, 1066, 1034, 
699 cm-1; 1H NMR (400 MHz, CDCl3) δ 12.68 (s, 1H), 9.71 (s, 1H), 7.22 (m, 9H), 4.80 (s, 1H), 
4.09 (tdd, J = 10.8, 7.1, 3.6 Hz, 2H), 3.35 (m, 1H), 3.02 (dd, J = 18.3, 12.4 Hz, 2H), 2.79 (dd, J = 
18.4, 5.5 Hz, 1H), 1.02 (t, J = 7.1 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 201.6, 172.9, 171.9, 
161.8, 159.3, 140.3, 129.5, 129.0, 127.7, 127.4, 124.2, 124.2, 115.9, 115.7, 97.2, 60.9, 56.9, 34.9, 
32.3, 32.3, 31.2, 14.1 ppm; the enantiomeric excess was determined by HPLC with an AD-H 
column  (n-hexane:  i-PrOH  =  97:3),  0.5  mL/min;  major  enantiomer  tR  =  27.1  min,  minor 










carboxylate, Yellow amorphous solid. [α]D23 = +123.4 (c=1.7, CHCl3, 98% ee ); IR (thin film, 
KBr): 2926, 2851, 2731, 1724, 1654, 1620, 1498, 1277, 1239, 1218, 1096, 1060, 828, 761, 741, 
701 cm-1; 1H NMR (400 MHz, CDCl3) δ 12.49 (s, 1H), 9.07 (d, J = 4.0 Hz, 1H), 7.25 (m, 6H), 
6.31 (d, J = 1.9 Hz, 1H), 6.08 (d, J = 3.0 Hz, 1H), 4.43 (d, J = 4.9 Hz, 1H), 4.15 (q, J = 7.1 Hz, 
2H), 3.55 (td, J = 11.8, 6.2 Hz, 1H), 2.93 (dt, J = 12.4, 4.5 Hz, 1H), 2.81 (dd, J = 18.9, 6.2 Hz, 
1H), 2.52 (dd, J = 18.9, 11.3 Hz, 1H), 1.15 (t, J = 7.1 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 
203.1, 171.9, 171.4, 153.9, 141.9, 141.2, 129.1, 127.7, 127.4, 110.3, 108.5, 97.9, 60.7, 54.4, 37.5, 
36.4, 35.1, 14.0 ppm; the enantiomeric excess was determined by HPLC with an AS-H column 
(n-hexane: i-PrOH = 97:3), 0.5 mL/min; major enantiomer tR = 32.7 min, minor enantiomer tR = 










Clear oil. [α]D23 = +18.5 (c=1.1, CHCl3, 91% ee ); IR (thin film, KBr): 2982, 2936, 2736, 1724, 
1660, 1624, 1406, 1371, 1264, 1218, 1183, 1069, 1032, 830, 758, 737, 699 cm-1; 1H NMR (400 
MHz, CDCl3) δ 12.44 (s, 1H), 9.54 (s, 1H), 7.34 (dt, J = 12.5, 7.8 Hz, 5H), 4.25 (m, 4H), 4.01 (d, 
J = 1.5 Hz, 1H), 3.49 (m, 1H), 3.30 (s, 1H), 2.77 (ddd, J = 23.4, 18.3, 8.6 Hz, 2H), 1.30 (dd, J = 
12.9, 7.1 Hz, 6H); 13C NMR (101 MHz, CDCl3) δ  200.2, 173.6, 171.7, 171.5, 139.3, 128.9, 
127.4,  95.5,  61.4,  60.8,  53.5,  39.4,  36.4,  30.7,  14.4,  14.1 ppm; the enantiomeric excess was 
determined by HPLC with an AS-H column (n-hexane:  i-PrOH = 97:3),  0.5 mL/min;  major 
enantiomer tR = 21.2 min, minor enantiomer tR = 32.3 min; HRMS (ESI) calcd for C19H22O6  [M-









carboxylate, Clear oil. [α]D23 = -44.5 (c=2.23, CHCl3, 98% ee ); IR (thin film, KBr): 2956, 2930, 
2871, 1722, 1617, 1403, 1261, 1213, 1064, 831, 698 cm-1; 1H NMR (400 MHz, CDCl3) δ 12.45 
(s, 1H), 9.60 (s, 1H), 7.32 (ddd, J = 17.9, 12.8, 5.6 Hz, 5H), 4.27 (dddd, J = 25.1, 10.8, 7.1, 3.7 
Hz, 2H), 3.45 (m, 1H), 3.00 (m, 2H), 2.89 (d, J = 1.7 Hz, 1H), 2.64 (dd, J = 18.5, 5.8 Hz, 1H), 
1.78 (m, 1H), 1.40 (m, 8H), 0.96 (dd, J = 9.7, 3.9 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 202.8, 
172.2, 170.8, 140.9, 128.8, 127.5, 127.0, 100.6, 60.6, 53.2, 34.6, 34.2, 32.8, 31.0, 30.1, 22.4, 
14.2, 14.0 ppm; the enantiomeric excess was determined by HPLC with an AS-H column (n-
hexane: i-PrOH = 99:1), 0.3 mL/min; major enantiomer tR = 26.3 min, minor enantiomer tR = 










biphenyl]-4-carboxylate, Clear oil.  [α]D23  = +106.1 (c=0.47, CHCl3, 97% ee );  IR (thin film, 
KBr): 2927, 2837, 1723, 1653, 1513, 1306, 1278, 1250, 1214, 1179, 1062, 1035, 1012, 831, 737 
cm-1; 1H NMR (400 MHz, CDCl3) δ 12.47 (s, 1H), 9.04 (d, J = 4.2 Hz, 1H), 7.33 (m, 1H), 7.08 
(d, J = 8.6 Hz, 2H), 6.83 (d, J = 8.6 Hz, 2H), 6.30 (dd, J = 2.9, 1.9 Hz, 1H), 6.07 (d, J = 3.2 Hz, 
1H), 4.40 (d, J = 5.0 Hz, 1H), 4.14 (q, J = 7.1 Hz, 2H), 3.76 (s, 3H), 3.50 (td, J = 11.7, 6.1 Hz, 
1H), 2.83 (m, 2H), 2.48 (dd, J = 18.9, 11.3 Hz, 1H), 1.15 (t, J = 7.1 Hz, 3H); 13C NMR (101 
MHz, CDCl3) δ 203.4, 172.0, 171.4, 158.8, 153.9, 141.8, 133.1, 128.7, 114.5, 110.3, 108.4, 97.9, 
60.7, 55.2, 54.6, 37.7, 35.6, 35.2, 14.0 ppm; the enantiomeric excess was determined by HPLC 
with an AS-H column (n-hexane: i-PrOH = 90:10), 0.5 mL/min; major enantiomer tR = 33.7 min, 










terphenyl]-4'-carboxylate, Colorless crystals. m.p.: 118-120oC; [α]D24 = +81.6 (c=0.53, CHCl3, 
99% ee ); IR (thin film, KBr): 2924, 2853, 1723, 1653, 1488, 1406, 1287, 1258, 1215, 1095, 
1072, 1009, 821 cm-1; 1H NMR (400 MHz, CDCl3) δ 12.63 (s, 1H), 9.64 (s, 1H), 7.44 (dd, J = 
22.2, 8.5 Hz, 4H), 7.12 (d, J = 8.3 Hz, 2H), 6.99 (d, J = 8.3 Hz, 2H), 4.38 (d, J = 1.7 Hz, 1H), 
4.06 (tt, J = 7.1, 3.5 Hz, 2H), 3.27 (m, 1H), 2.90 (m, 2H), 2.74 (dd, J = 18.4, 5.4 Hz, 1H), 1.02 (t, 
J = 7.1 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 200.9, 171.9, 171.6, 142.9, 138.9, 131.8, 131.7, 
129.3, 129.1, 121.1, 120.6, 97.5, 60.8, 58.7, 38.4, 33.7, 30.9, 13.9 ppm; the enantiomeric excess 
was determined by HPLC with an AS-H column (n-hexane: i-PrOH = 97:3), 0.5 mL/min; major 
enantiomer tR = 22.0 min, minor enantiomer tR = 31.0 min. HRMS (ESI) calcd for C22H20Br2O4 











biphenyl]-4-carboxylate, Clear oil.  [α]D26  = +120.3 (c=0.71, CHCl3, 93% ee );  IR (thin film, 
KBr): 2983, 2930, 2826, 2731, 1725, 1654, 1622, 1491, 1406, 1307, 1232, 1217, 1097, 1061, 
1038, 758 cm-1; 1H NMR (400 MHz, CDCl3) δ 12.48 (s, 1H), 9.14 (d, J = 3.6 Hz, 1H), 7.33 (dd, J 
= 1.8, 0.8 Hz, 1H), 7.11 (m, 4H), 6.30 (dd, J = 3.2, 1.9 Hz, 1H), 6.09 (d, J = 3.2 Hz, 1H), 4.46 (d, 
J = 5.0 Hz, 1H), 4.15 (q, J = 7.1 Hz, 2H), 3.84 (td, J = 11.8, 6.3 Hz, 1H), 3.07 (m, 1H), 2.81 (dd, 
J = 18.8, 6.3 Hz, 1H), 2.59 (dd, J = 18.8, 11.3 Hz, 1H), 1.16 (t, J = 7.1 Hz, 3H); 13C NMR (101 
MHz, CDCl3)  δ  202.5,  171.7,  171.4,  162.0,  159.6,  153.7,  141.9,  129.1,  129.1,  129.0,  128.9, 
128.1, 127.9, 124.8, 124.7, 116.1, 115.9, 110.4, 108.5, 97.9, 60.7, 53.6, 53.5, 35.4, 34.8, 30.3, 
14.0 ppm; the enantiomeric excess was determined by HPLC with an AS-H column (n-hexane: i-
PrOH = 97:3), 0.5 mL/min; major enantiomer tR = 31.3 min, minor enantiomer tR = 18.5 min. 










oil. [α]D26 = +65.3 (c=0.58, CHCl3, 95% ee ); IR (thin film, KBr): 2925, 2853, 1723, 1654, 1407, 
1276, 1217, 1094, 1067, 1012, 812, 736 cm-1; 1H NMR (400 MHz, CDCl3) δ 12.57 (s, 1H), 9.69 
(s, 1H), 7.35 (m, 2H), 6.31 (ddd, J = 19.6, 3.2, 1.8 Hz, 2H), 6.13 (m, 1H), 6.00 (dt, J = 3.2, 0.8 
Hz, 1H), 4.49 (s, 1H), 4.16 (m, 2H), 3.50 (m, 1H), 3.32 (m, 1H), 2.74 (m, 2H), 1.16 (t, J = 7.1 
Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 201.2, 171.7, 171.0, 156.1, 154.1, 141.8, 141.7, 110.4, 
110.2, 107.0, 106.1, 96.9, 60.7, 52.3, 32.6, 30.1, 30.0, 14.0 ppm; the enantiomeric excess was 
determined by HPLC with an AS-H column (n-hexane:  i-PrOH = 95:5),  1.0 mL/min;  major 
enantiomer tR = 17.9 min, minor enantiomer tR = 25.2 min. HRMS (ESI) calcd for C18H18O6 [M
+Na]+ 353.1000, found 353.0992.
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no C4 epimer detected
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6.3 Experimental and Characterization for Chapter 4
Assignment of Stereochemistry 
Stereochemistry  was  assigned  based  on  the  accepted  model  of  stereochemical  induction  of 
catalyst 1.32,[1] and the prior determination of stereochemistry for β-amination of substrate 1.33f 
using catalyst 1.32.[2]
Preparation of catalysts (1.32, 1.32r), starting enals (1.33e-j), and amine nucleophiles (2.18, 
4.18)
Catalysts  1.32  and  1.32r  were  prepared  according  to  literature  procedures  from  the 
corresponding  diarylprolinols.[3]  Non-commercially  available  enals  1.33e,[4a]  1.33f,[4b]  1.33g,[4c] 
1.33h,[4d]  1.33i,[4e]  and  1.33j[4f]  and  were  prepared  according  to  known  procedures.  Amine 
nucleophiles (2.18, 4.18) were prepared according to known literature procedures.[5]
General Procedure for amino-difluorination
To a solution of catalyst 1.32 (0.05 mmol, 0.2 equiv) and amine (0.5 mmol, 2 equiv) in MTBE 
(0.4 mL) was added enal 1.33a (0.25 mmol, 1 equiv). After  ≥95% consumption of enal 1.33a 
(1d, 1H NMR), the reaction was diluted with MTBE (0.6 mL), followed by addition of NFSI (0.5 
mmol, 2 equiv), then catalyst 1.32r (0.05 mmol, 0.2 equiv). The mixture was stirred vigorously 
until >85% (or, in some cases, complete) consumption of intermediate β-aminoaldehyde and α-
fluoro-β-aminoaldehyde (2d, 1H NMR). The reaction mixture was then diluted with Et2O (2 mL), 
cooled to  -8°C and filtered through silica  gel  (2”  in  a  pipette),  eluting with  a  cold  (-50°C) 
solution of 9:1 Et2O:DCM (30 mL). Me2S (0.2 mL) was added to the eluent at rt and the mixture 
stirred for 15 minutes, then transferred to a separatory funnel and washed with sat. NaHCO3 (2 x 
50  mL)  and  brine.  The  combined  extracts  were  dried  over  MgSO4  and  concentrated.  The 
resulting residue was dissolved in 2:1 DCM : EtOH (2 mL), followed by the addition of NaBH4 
(0.625 mmol, 2.5 equiv) in one portion. After stirring for 30min the reaction was cooled to 0°C 
and quenched by the slow addition of sat. NH4Cl (5 mL). The mixture was then warmed to rt and 
stirred vigorously for 30 min. The mixture was extracted with DCM (2 x 50 mL), the organics 
washed with  brine  and  dried  over  MgSO4,  then  concentrated.  Purification  on  silica  gel  was 
achieved (unless otherwise noted) using 19:1 DCM : pet. ether until the excess unreacted amine 
nucleophile  was  free  of  the  column,  then  switching  to  19:1  DCM  :  Et2O  to  elute 










(R)-benzyl-(2,2-difluoro-1-hydroxyheptan-3 yl)(methoxy)carbamate: pale yellow liquid (44.3 
mg, 54% yield, 91% ee). [α]23D = +2.8 (c 1.8, CHCl3); IR (thin film, KBr): 3454, 2959, 292, 
2859, 113, 145, 1403, 1320, 1286, 1219, 1139, 109, 100, 912, 58, 36 cm-1; 1H NMR (400 MHz, 
CDCl3) δ .44 – .31 (m, 5H), 5.26 (q, J = 12.2 Hz, 2H), 4.52 – 4.39 (m, 1H), 3.89 – 3.65 (m, 5H), 
3.10 (s, 1H), 2.05 – 1.88 (m, 1H), 1.81 – 1.64 (m, 1H), 1.44 – 1.14 (m, 4H), 0.88 (t, J = .1 Hz, 
3H); 13C NMR (101 MHz, CDCl3) δ 158.4, 135.5, 128. (2C), 128.5, 128.1 (2C), 121.4 (t, J = 
249.3 Hz, 1C), 68.6, 63.5, 62.9 – 61.8 (m, 1C), 59.8, 28.0, 22., 22.3, 13.8; 19F NMR (188 MHz, 
CDCl3) δ  = -113.4 (d, JF-F  = 258.6 Hz, 1F), -118.9 (d, J  = 262.6 Hz, 1F); ee (HPLC, AD-H 
column) (n-hexane/i-PrOH = 95:5),  0.3 mL/min; major tR  = 42.4 min,  minor tR  = 56.1 min. 




























































































































(R)-benzyl-(2,2-difluoro-1-hydroxypentan-3-yl)(methoxy)carbamate:  colorless  liquid  (43.3 
mg, 57% yield, 90% ee). [α]23D = +10.9 (c 2.1, CHCl3); IR (thin film, KBr): 3453, 295, 2944, 
112, 145, 1402, 1359, 1314, 1263, 1214, 1143, 10, 1028, 56 cm-1; 1H NMR (400 MHz, CDCl3) δ .
3 (h, J = 4.9 Hz, 5H), 5.26 (q, J = 12.2 Hz, 2H), 4.46 – 4.31 (m, 1H), 3.92 – 3.62 (m, 5H), 3.0 (s, 
1H), 1.9 (ddt, J = 18., 14.4, .3 Hz, 1H), 1.88 – 1.3 (m, 1H), 0.96 (t, J = .3 Hz, 3H); 13C NMR (101 
MHz, CDCl3) δ 158.6, 135.5, 128. (2C), 128.5, 128.1 (2C), 121.4 (t, J = 249.3 Hz, 1C), 68.6, 
63.6, 62.8 – 61.9 (m, 1C), 61.9 – 61.0 (m, 1C), 16.5, 10.6; 19F NMR (188 MHz, CDCl3) δ = 
-113.5 (d, JF-F = 25.6 Hz, 1F), -118. (d, JF-F = 263.3 Hz, 1F) ppm; ee (HPLC, AS-H column) (n-
hexane/i-PrOH = 95:5), 0.3 mL/min; major tR = 34.2 min, minor tR = 31.5 min. HRMS (ESI) [M 




































































































































(R)-benzyl-(2,2-difluoro-1-hydroxyhexan-3-yl)(methoxy)carbamate: pale yellow liquid (40.9 
mg, 52% yield, 98% ee); [α]23D = +3.8 (c 1.2, CHCl3); IR (thin film, KBr): 3462, 2962, 285, 112, 
145, 1402, 1299, 1239, 1139, 108, 1016, 914, 5 cm-1; 1H NMR (400 MHz, CDCl3) δ .43 – .29 (m, 
5H), 5.25 (q, J = 12.2 Hz, 2H), 4.55 – 4.41 (m, 1H), 3.90 – 3.63 (m, 5H), 3.08 (s, 1H), 2.05 – 
1.90 (m, 1H), 1.3 – 1.62 (m, 1H), 1.52 – 1.3 (m, 1H), 1.34 – 1.20 (m, 1H), 0.92 (t, J = .4 Hz, 
3H); 13C NMR (101 MHz, CDCl3) δ 158.4, 135.5, 128. (2C), 128.5, 128.1(2C), 121.4 (t, J = 
249.3 Hz, 1C) 68.6, 63.6, 62.8 – 61.9 (m, 1C), 59.5 (t, J = 26. Hz, 1C), 25.0, 19.1, 13.6; 19F NMR 
(188 MHz, CDCl3) δ = -113.4 (d, JF-F = 25.8 Hz, 1F), -118.8 (d, JF-F = 28.3 Hz, 1F) ppm; ee 
(HPLC, AD-H column) (n-hexane/i-PrOH = 95:5), 0.3 mL/min; major tR = 42.4 min, minor tR = 































































































































(R)-benzyl-(2,2-difluoro-1-hydroxydodecan-3-yl)(methoxy)carbamate: Chromatography (3% 
acetone in pet. ether) gave a yellow liquid (49.5 mg, 49% yield, 92% ee). [α]23D = +.5 (c 2.6, 
CHCl3); IR (thin film, KBr) 3462, 292, 2855, 113, 145, 1401, 1304, 1085, 911, 56 cm-1; 1H NMR 
(400 MHz, CDCl3) δ .42 – .31 (m, 5H), 5.26 (q, J = 12.2 Hz, 2H), 4.55 – 4.3 (m, 1H), 3.90 – 
3.62 (m, 5H), 3.10 (s, 1H), 2.05 – 1.8 (m, 1H), 1.9 – 1.60 (m, 1H), 1.41 – 1.20 (m, 14H), 0.88 (t, 
J = 6.9 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 158.6, 135.6, 128. (2C), 128.6, 128.2 (2C), 
121.6 (t, J = 249.2 Hz, 1C), 68.6, 63.6, 62.9 – 62.0 (m, 1C), 59.9 (t, J = 23.9 Hz, 1C), 32.0, 29.6, 
29.5, 29.4, 29.3, 26.0, 23.2, 22.8, 14.2; 19F NMR (188 MHz, CDCl3) δ = -113.4 (d, JF-F = 261.0 
Hz, 1F), -118.9 (d, JF-F = 266.2 Hz, 1F) ppm; ee (HPLC, AD-H column) (n-hexane/i-PrOH = 
9:3), 0.3 mL/min; major tR = 41.6 min, minor tR = 48.6 min. HRMS (ESI) [M + H]+ calcd for 















































































































































(R)-benzyl-(2,2-difluoro-1-hydroxy-5phenylpentan-3-yl)(methoxy)   carbamate:  colorless 
liquid (41.1 mg, 43% yield, 93% ee); [α]23D = +13.8 (c 1.0, CHCl3); IR (thin film, KBr): 3461, 
3029, 2944, 112, 149, 1455, 1402, 1309, 1214, 110, 1102, 10, 1018, 913, 52 cm-1; 1H NMR (400 
MHz, CDCl3) δ .42 – .10 (m, 10H), 5.38 – 5.1 (m, 2H), 4.53 – 4.39 (m, 1H), 3.88 – 3.60 (m, 5H), 
3.14 (s, 1H), 2.8 (ddd, J = 14.0, 9., 4.5 Hz, 1H), 2.54 (dt, J = 13.8, 8.3 Hz, 1H), 2.39 – 2.24 (m, 
1H), 2.13 – 2.01 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 158.4, 140., 135.5, 128.8 (2C), 128., 
128.6 (2C), 128.5 (2C), 128.3 (2C), 126.4, 121.50 (t, J = 249.6 Hz, 1C), 68.8, 63.8, 63.2 – 61.3 
(m, 1C), 59.3 (t, J = 28.5 Hz, 1C), 32.1, 25.0; 19F NMR (188 MHz, CDCl3) δ = -113.4 (d, JF-F = 
263.1 Hz, 1F), -119.1 (d, JF-F = 20.0 Hz, 1F) ppm; ee (HPLC, AD-H column) (n-hexane/i-PrOH = 
95:5), 0.5 mL/min; major tR = 42.4 min, minor tR = 50.9 min. HRMS (ESI) [M + H]+ calcd for 













































































































































(R)-benzyl-(2,2-difluoro-1-hydroxy-5-methylhexan-3-yl)(methoxy)  carbamate:   colorless 
liquid (40.8 mg, 49% yield, 88% ee). [α]23D = +.3 (c 1.2, CHCl3); IR (thin film, KBr) 3460, 2959, 
282, 112, 1456, 1402, 1305, 1244, 1085, 1002, 912, 55 cm-1; 1H NMR (400 MHz, CDCl3) δ .43 
– .30 (m, 5H), 5.26 (q, J = 12.2 Hz, 2H), 4.64 – 4.49 (m, 1H), 3.89 – 3.66 (m, 5H), 3.20 (s, 1H), 
2.01 (ddd, J = 14., 11.6, 3.4 Hz, 1H), 1.6 – 1.55 (m, 1H), 1.41 (t, J = 12.4 Hz, 1H), 0.95 (d, J = 
6.6 Hz, 3H), 0.86 (d, J = 6.5 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 158.3, 135.4, 128.6 (2C), 
128.5, 128.1 (2C), 121.6 (t, J = 249.4 Hz, 1C), 68.6, 63.6, 62.8 – 61.6 (m, 1C), 5., 31., 24.4, 23.5, 
21.1; 19F NMR (188 MHz, CDCl3) δ = -113.2 (d, JF-F = 25.4 Hz, 1F), -119.0 (d, JF-F = 260.1 Hz, 
1F) ppm; ee (HPLC, AD-H column) (n-hexane/i-PrOH = 95:5), 0.3 mL/min; major tR = 31.6 min, 


































































































































(R)-benzyl-(2,2-difluoro-1-hydroxy-4-methylpentan-3-yl)(methoxy)  carbamate:  colorless 
liquid (31.4 mg, 40% yield, 90% ee). [α]23D = +1.0 (c 0.9, CHCl3); IR (thin film, KBr) 3480, 
2968, 2946, 289, 112, 145, 1394, 1350, 1305, 12, 1213, 1148, 105, 1004, 912, 56 cm-1; 1H NMR 
(400 MHz, CDCl3) δ .44 – .31 (m, 5H), 5.32 – 5.18 (m, 2H), 4.21 (d, J = 1.4 Hz, 1H), 3.9 – 3.64 
(m, 5H), 2.92 (s, 1H), 2.39 (d, J = 6.9 Hz, 1H), 1.11 (dd, J = 6.3, 3.1 Hz, 3H), 1.04 (d, J = 6. Hz, 
3H); 13C NMR (101 MHz, CDCl3) δ 158.5, 135.5, 128. (2C), 128.5, 128.1 (2C), 122.4 (t, J = 
251.0 Hz, 1C), 68.6, 64.6, 63.8 – 63.1 (m, 1C), 63.1, 26.1, 20.6, 19.8 (d, J = 6.2 Hz, 1C) ppm; 19F 
NMR (188 MHz, CDCl3) δ = -105.3 – -11.1 (m, 2F) ppm; ee (HPLC, AS-H column) (n-hexane/i-
PrOH = 9:3), 0.3 mL/min; major tR = 35.4 min, minor tR = 50.9 min. HRMS (ESI) [M + H]+ 

























































































































(R)-benzyl-(2,2-difluoro-1-hydroxyoct--en-3-yl)(methoxy)carbamate: yellow liquid (40.8 mg, 
4% yield, 91% ee). [α]23D = +8.4 (c 1., CHCl3); IR (thin film, KBr) 3458, 2942, 112, 1456, 1401, 
1316, 1213, 1165, 1080, 1016, 913, 55 cm-1; 1H NMR (400 MHz, CDCl3) δ .42 – .32 (m, 5H), 5.5 
(ddt, J = 16.9, 10.2, 6. Hz, 1H), 5.26 (q, J = 12.2 Hz, 2H), 5.05 – 4.93 (m, 2H), 4.54 – 4.40 (m, 
1H), 3.88 – 3.6 (m, 5H), 3.05 (s, 1H), 2.13 – 1.90 (m, 3H), 1.81 – 1.6 (m, 1H), 1.5 – 1.44 (m, 
1H), 1.43 – 1.28 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 158.3, 13.9, 135.4, 128. (2C), 128.5, 
128.1 (2C), 121.4 (t, J = 249.4 Hz, 1C), 115.1, 68.6, 63.6, 62.4 (dd, J = 32.8, 30.1 Hz, 1C), 60.8 
– 58.6 (m, 1C), 33.2, 25.1, 22.5; 19F NMR (188 MHz, CDCl3) δ = -113.4 (d, JF-F = 25.4 Hz, 1F), 
-118. (d, JF-F = 246.6 Hz, 1F) ppm; ee (HPLC, AD-H column) (n-hexane/i-PrOH = 95:5), 0.3 mL/















































































































































(R)-benzyl-(1-(benzyloxy)-3,3-difluoro-4-hydroxybutan-2-yl)(methoxy)  carbamate: 
Chromatography (12.5% to 20% EtOAc in pet. ether) gave a colorless liquid (43.6 mg, 44% 
yield, 92% ee). [α]23D = +6.9 (c 1.8, CHCl3); IR (thin film, KBr) 3461, 2926, 116, 1455, 1396, 
1303, 1120, 106, 1028, 910, 3 cm-1; 1H NMR (400 MHz, CDCl3) δ .42 – .28 (m, 10H), 5.32 – 
5.20 (m, 2H), 4.86 (dtd, J = 1.8, 9.3, 4.3 Hz, 1H), 4.56 (s, 2H), 4.04 (t, J = 9.8 Hz, 1H), 3.90 – 
3.1 (m, 6H), 2.90 (s, 1H); 13C NMR (101 MHz, CDCl3) δ 158.3, 13.5, 135.5, 128.6 (2C), 128.4 
(2C), 128.1 (2C), 12.8 (2C), 12. (2C), 121.1 (t, J = 249.6 Hz, 1C), 3.3, 68.6, 63., 63.3, 62.6 (t, J = 
31.1 Hz, 1C), 59.5 (t, J = 25.8 Hz, 1C); 19F NMR (188 MHz, CDCl3) δ = -113.0 (d, JF-F = 253.9 
Hz, 1F), -115.8 (d, JF-F  = 23.0 Hz, 1F) ppm; ee (HPLC, AD-H column) (n-hexane/i-PrOH = 
90:10), 1.0 mL/min; major tR = 1.6 min, minor tR = 20.0 min. HRMS (ESI) [M + H]+ calcd for 


































































































































(R) -methy l -9 - ( ( (benzy loxy)carbony l ) (methoxy)amino) -10 ,10 -d ifluoro-11 -
hydroxyundecanoate: Chromatography (12.5% to 20% EtOAc in pet. ether) gave a colorless 
liquid (50.5 mg, 47% yield, 90% ee). [α]23D = +3.2 (c 2.8, CHCl3); IR (thin film, KBr) 3999, 
2941, 2858, 13, 1456, 1399, 1303, 1213, 111, 1115, 109, 1015, 912, 56 cm-1; 1H NMR (400 MHz, 
CDCl3) δ .41 – .31 (m, 5H), 5.25 (q, J = 12.2, 11.4 Hz, 2H), 4.53 – 4.38 (m, 1H), 3.91 – 3.64 (m, 
8H), 3.11 (s, 1H), 2.29 (t, J = .5 Hz, 2H), 2.01 – 1.90 (m, 1H), 1.69 (s, 1H), 1.63 – 1.56 (m, 2H), 
1.45 – 1.16 (m, 8H); 13C NMR (101 MHz, CDCl3) δ 14.6, 158.8, 135.8, 129.0 (2C), 128.9, 128.5 
(2C), 121.8 (t, J = 249.3 Hz, 1C), 68.9, 63.9, 63.2 – 62.2 (m, 1C), 60.9 – 60.0 (m, 1C), 51.8, 
34.4, 29.3, 29.3, 29.3, 26.1, 25.2, 23.2; 19F NMR (188 MHz, CDCl3) δ = -113.4 (d, JF-F = 258.3 
Hz, 1F), -118.8 (d, JF-F = 259.9 Hz, 1F) ppm; ee (HPLC, AD-H column) (n-hexane/i-PrOH = 
90:10), 1.0 mL/min; major tR = 12.8 min, minor tR = 15.6 min. HRMS (ESI) [M + H]+ calcd for 


















































































































































(R)-benzyl-benzyloxy(2,2-difluoro-1-hydroxydodecan-3-yl)carbamate: prepared according to 
the general procedure (3.0 mmol scale), using the N-OBn protected amine nucleophile (4.18). 
Chromatography (5-15% EtOAc in pet. ether) of the crude cascade product gave an inseparable 
mixture  of  alcohol  2.34k  and  unreacted  amine  nucleophile  in  an  approximate  2:3  ratio, 
respectively. Yield was determined by NMR, using cyclohexene as internal standard (54% yield). 











Prepared from adapted literature procedures.30 To an inseperable mixture of difluoroaminoalcohol 
2.34k (0.53 mmol, as determined by NMR with internal standard) and the amine nucleophile (1.4 
mmol) in MeCN (10 mL, 0.2 M) was added NMO (2.34 g, 10 equiv), H2O (360 µL, 10 equiv) 
and TPAP (0.3 mg, 0.10 equiv) and stirred at rt for 1.5 hrs, followed by quenching with i-PrOH 
(5 mL) and stirring for 30 min. The crude mixture was filtered through silica gel (4” plug) with 
9 : 1 DCM : MeOH (150 mL), and the eluent concentrated. The resulting crude residue was 
dissolved (Et2O, 50 mL) and washed with sat. KHSO4 (2 x 50 mL) to remove the excess NMO, 
and the aqueous layer again extracted (Et2O, 2 x 20 mL). The combined organic extracts were 
washed with brine, dried over Na2SO4 and concentrated. Column chromatography (8:2 EtOAc : 
PE to 9:1 EtOAc : MeOH) afforded the carboxylic acid (yellow oil) in nearly quantitative yield 
(260 mg, 0.53 mmol). 
To this acid intermediate (260 mg, 0.53 mmol) in methanol (4.0 mL) at 0℃, was added dropwise 
AcCl (3 µL,  10 equiv).  The mixture was warmed to rt,  stirred for  2 hrs  (when the starting 
material was confirmed consumed by TLC) then concentrated. This crude residue was dissolved 
(EtOAc, 50 mL), neutralized with sat. NaHCO3 (50 mL), washed with brine (50 mL), then dried 
over MgSO4. Concentration provided the pure methyl ester (4.19) as a colorless liquid (261 mg, 
98% yield, 89% ee). [α]23D = +50.4 (c 3.5, CHCl3); IR (thin film, KBr) 3066, 3034, 2956, 2926, 
2855, 16, 119, 1498, 1456, 1389, 1285, 1215, 1066, 51 cm-1; 1H NMR (400 MHz, CDCl3) δ .4 – .
173
1
28 (m, 10H), 5.24 (s, 2H), 4.99 – 4.81 (m, 2H), 4.82 – 4.58 (m, 1H), 3.6 (s, 3H), 2.1 – 1.91 (m, 
1H), 1.3 – 1.52 (m, 1H), 1.40 – 1.11 (m, 14H), 0.94 – 0.81 (m, 3H); 13C NMR (101 MHz, CDCl3) 
δ 163.9 (t, J = 32.2 Hz, 1C), 15.8, 135.6, 135.0, 129.4 (2C), 128.6 (2C), 128.5, 128.4, 128.4 
(2C), 128.2 (2C), 114. (t, J = 256.3 Hz, 1C), .9, 68.5, 61.3 (t, J = 25.8 Hz, 1C), 53.4, 31.9, 29.4, 
29.3, 29.3, 29.1, 25.3, 23.5, 22., 14.1; 19F NMR (188 MHz, CDCl3) δ = -109.9 (dd, JF-F = 259., JF-
H = 9.4 Hz, 1F), -115.3 (d, JF-F = 256.6 Hz, 1F) ppm; ee (HPLC, AD-H column) (n-hexane/i-
PrOH = 99:1), 0.3 mL/min; major tR = 26.6 min, minor tR = 59.2 min. HRMS (ESI) [M + H]+ 































































































































































(R)-methyl-3-amino-2,2-difluorododecanoate: Difluoroaminoester 4.19 (5 mg, 0.11 mmol) in 
MeOH (5 mL) was slowly added to a slurry of 5% Pd/C (4 mg, 20% Pd) in EtOH (0.5 mL) and 
hydrogenated (50 psi) at rt for 20 hrs. This crude mixture was filtered through cotton (EtOAc, 30 
mL) and concentrated to give the pure free amino ester (4.14), as a yellow oil (2.3 mg, 91% 
yield); [α]23D = +19.6 (c 0., CHCl3); IR (thin film, KBr) 340, 2956, 2926, 2856, 164, 1459, 1441, 
138, 1316, 1196, 109, 812, 23 cm-1; 1H NMR (400 MHz, CDCl3) δ 3.89 (s, 3H), 3.28 – 3.11 (m, 
1H), 1.66 – 1.50 (m, 2H), 1.34 – 1.21 (m, 14H), 0.88 (t, J = 6.6 Hz, 3H); 13C NMR (101 MHz, 
CDCl3) δ 164.2 (t, J = 32.9 Hz, 1C), 116.35 (t, J = 253.3 Hz, 1C), 54.32 (t, J = 24.1 Hz, 1C), 
53.2, 31.9, 29. (t, J = 2.5 Hz, 1C), 29.5, 29.4, 29.4, 29.3, 25.8, 22., 14.1; 19F NMR (188 MHz, 
CDCl3) δ = -115.3 (dd, JF-F = 256.4, JF-H = 11.3 Hz, 1F), -118.4 (dd, JF-F = 256.5, JF-H = 14.2 Hz, 
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6.4 Experimental and Characterization for Chapter 5 
Determination of Diastereomeric Ratios for Products 5.14a-5.14i
As products 5.14a-5.14i were isolated as inseparable mixtures of diastereomers, diastereomeric 
ratios  (dr)  were  determined  using  1H  NMR spectroscopy  to  compare  integral  ratios  for  the 
major : minor diastereomers. Spectral peaks of individual diastereomers were chosen based on 
the best separation of diastereomer peaks. Typically, these peaks were in one of two regions: the 
aldehyde region (9-10ppm), or the alkyl region (2-3ppm.) Inserts into the 1H NMR spectra are 
provided to demonstrate determination of dr. 
General Procedure B, for Reductive Cyclization
To an oven-dried, 10 mL round bottom flask (fitted with rubber septum and magnetic stir bar) 
was added DiPiBA (N,N-diisopropyl-N-isobutylamine) (256 µL, 10 equiv), morpholine (11 µL 1 
equiv), MeCN (1.5mL) (followed by wrapping the flask with aluminum foil to minimize light 
exposure), and a stock solution of MeCN containing tris(2,2 ́-bipyridyl)ruthenium(II) dichloride 
hexahydrate (1.0 mL, 2.5 mg per mL, 2.5 mol%) for a total of 2.5 mL MeCN. The solution was 
then bubbled though with Argon for 15 min (equivalent results were achieved with 3X degassing 
by freeze-pump-thaw.) The starting enal (0.125 mmol, 1 equiv) was then added, the aluminum 
foil  removed,  and the flask sealed with a yellow cap and parafilm. The reaction was stirred 
rapidly (DiPiBA was poorly soluble in MeCN) and irradiated overnight (12 hrs) using a 1600 
lumen (23 Watt) broad spectrum fluorescent bulb, placed approximately 10cm from the reaction 
flask. After 12 hrs, morpholine was again added (11 µL, 1 equiv) (with careful argon purging 
through  an  attached  rubber  septum,  and  re-sealing  with  cap  and  parafilm  after  morpholine 
addition), followed by an additional 4 hours of irradiation (16 hrs total reaction time.) 
Work-up consisted of diluting the reaction mixture with EtOAc (~1 mL) and filtering through a 
4”  plug  of  silica,  flushing  with  additional  (EtOAc,  120  mL.)  The  resulting  filtrate  was 
concentrated at the rotovap (40oC, 125mbar), followed by high vacuum (15-30 min), before a 
crude NMR yield was attained using cyclohexene (1 equiv) as internal standard, or equivalently 
using the ester -CH2 quartet at 4.21 ppm as standard from which the product aldehyde conversion 
could be calibrated. Isolated yields were obtained by silica chromatography, as indicated for the 
individual substrates. 
179
Preparation of amines (A1-A2)
A1:
N
A known compound, tertiary amine N,N-diisopropyl-N-isobutylamine (i.e., DiPiBA) (A1) was 






A known compound, morpholin-3-one (A2) was prepared according to literature.2
Preparation of starting enals (5.13a-i):
Unless otherwise noted, enal substrates were synthesized using adapted literature procedures, 
referenced in General Procedure A, which describes a representative procedure for enal 5.13a. 
This  was  used,  in  part  or  in  whole,  with  any  changes  noted  under  the  characterization  for 
individual enal substrates.
General Procedure A: 







3) Grubbs II, 
Crotonaldehyde, Tol.5.13a
1)  5-hexen-1-ol  (2.93  mL,  24.4  mmol)  was  added  dropwise  to  a  suspension  of  pyridinium 
chlorochromate (PCC, 7.90 g, 1.5 equiv) and celite (7.90 g) in DCM (66 mL), with cooling over 
an  ice/water  bath.  After  10  minutes,  the  cooling  bath  was  removed and the  solution  stirred 
vigorously for 2 h, when the alcohol was observed consumed (TLC, 5% EtOAc/PE; alcohol RF = 
0.1) (Note: the reaction could be left overnight before workup with little loss in yield.) The dark 
slurry was then diluted with Et2O (50 mL) and filtered through a pad of silica gel (4” x 3.0”), 
rinsing with 9:1 pentane : Et2O. The filtrate was concentrated (40°C, 500mbar) to give a crude 
mixture of the (volatile) desired aldehyde and DCM (~1:1), along with trace PCC impurities. 
Attempts at  further purification (chromatography,  distillation) were not  useful  and this  crude 
intermediate could be submitted to the following Wittig olefination without detriment.
2)  To  a  solution  of  stabilized  ylide  (carbethoxymethylene)triphenylphosphorane  (10.2  g,  1.2 
equiv) in THF (150 mL) was added a solution of the product aldehyde from the previous step 
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(assumed  full  conversion  of  24.4  mmol)  in  THF  (50  mL).  After  5  h,  the  reaction  was 
concentrated (40°C, 250 mbar), until most of the THF had been removed. The white sludge was 
then dissolved in Et2O (50 mL), and stirred rapidly for 10 min (precipitation of white OPPh3 
occurred).  Petroleum ether  (150 mL) was then added and the precipitated OPPh3 filtered off 
through a plug of packed celite (3” x 2.5”), rinsing with the same 25% Et2O/PE solution (100 
mL). The filtrate was concentrated (40°C, 500mbar), washed with brine (2 x 100 mL) and dried 
over MgSO4. Concentration (40°C, up to 300 mbar) gave 3.10 g (76% yield over 2-steps; 99% E-
isomer) of the desired ethyl ester as volatile, colorless oil, with purity sufficient for the following 
metathesis step.4
3) To a solution of the terminal alkene from step 2 (3.10 g, 18.43 mmol) in anhydrous toluene 
(140 mL), was added crotonaldehyde (97% E-isomer) (15.3 mL, 10 equiv) followed by Grubb’s 
II catalyst (782 mg, 5 mol %). The brown mixture was heated to 65°C and stirred for 5-15h (time 
depending upon the age of the Grubbs’ catalyst, which seemed to loose activity after a period of 
weeks  from  opening,  despite  storing  at  -20°C  under  argon)  until  the  starting  alkene  was 
consumed,  as  monitored  by  1H  NMR.  After  cooling  to  room  temperature,  the  solvent  was 
removed at the rotovap (40°C, 50 mbar.) Special care was then taken to remove the ruthenium 
residues from the Grubbs catalyst, as these were found to promote decomposition of the enal 
product on extended storage.5 Initials filtration through silica (6”, 20% EtOAc / PE), followed by 
a slower purification on silica (7.5% EtOAc / PE) was typically sufficient to remove Grubbs’ 
residues and stabilize the product  for  storage.  After  this  procedure,  the desired enal  (1)  was 
attained as a clear oil (2.68 g, 74% yield, >95% E-isomer).6








3) Grubbs II, 
Crotonaldehyde
ethyl (2E,7E)-9-oxonona-2,7-dienoate: Prepared exactly as described in General Procedure A, 
to give 2.68g (13.6 mmol) as a yellow oil; 56% overall yield from 5-hexen-1-ol; 1H NMR (400 
MHz, CDCl3): δ 9.52 (dd, J = 7.8, 0.7 Hz, 1H), 6.93 (dt, J = 15.6, 7.0 Hz, 1H), 6.82 (dt, J = 15.6, 
6.8 Hz, 1H), 6.13 (ddt, J = 15.6, 7.8, 1.1 Hz, 1H), 5.87-5.82 (m, 1H), 4.19 (qd, J = 7.1, 0.7 Hz, 
2H), 2.40-2.35 (m, 2H), 2.30-2.22 (m, 2H), 1.70 (quintet, J = 7.5 Hz, 2H), 1.31-1.26 (m, 3H); 13C 
NMR (101 MHz, CDCl3): δ 193.9, 166.4, 157.5, 147.7, 133.3, 122.2, 60.2, 31.9, 31.4, 26.1, 14.3 












3) Grubbs II, 
Crotonaldehyde
methyl (2E,7E)-9-oxonona-2,7-dienoate: Prepared according to General Procedure A, starting 
from  hex-5-enal  (7.0  mmol)  using  ylide  carbmethoxymethylene)triphenylphosphorane  (1.2 
equiv), which, after Grubbs’ metathesis and purification on silica gel (10% EtOAc / PE), afforded 
926mg (5.57 mmol) as a yellow oil; 80% overall yield from hex-5-enal; 1H NMR (400 MHz, 
CDCl3): δ 9.50 (d, J = 7.8 Hz, 1H), 6.93 (dt, J = 15.2, 7.4 Hz, 1H), 6.81 (dt, J = 15.1, 7.3 Hz, 
1H), 6.12 (dd, J = 15.6, 7.8 Hz, 1H), 5.84 (d, J = 15.7 Hz, 1H), 3.72 (s, 3H), 2.36 (q, J = 7.3 Hz, 
2H), 2.26 (q, J = 7.2 Hz, 2H), 1.69 (quintet, J = 7.4 Hz, 2H) ppm; 13C NMR (101 MHz, CDCl3): 
δ 193.9, 167.0, 157.4, 148.1, 133.5, 121.9, 51.6, 32.0, 31.5, 26.3 ppm; IR: 2992, 2948, 2854, 











ethyl (2E,7E)-5,5-dimethyl-9-oxonona-2,7-dienoate: Prepared by adopting step (3) of General 
Procedure A for use with known starting alkene ethyl (E)-5,5-dimethylocta-2,7-dienoate (874 
mg, 4.45 mmol).7 Purification on silica gel (5% EtOAc / PE) afforded 668 mg as a clear oil; 67% 
yield; 1H NMR (400 MHz, CDCl3): δ 9.52 (d, J = 7.9 Hz, 1H), 6.94 (dt, J = 15.5, 7.8 Hz, 1H), 
6.82 (dt, J = 15.5, 7.8 Hz, 1H), 6.15-6.08 (m, 1H), 5.83 (dt, J = 15.5, 1.3 Hz, 1H), 4.18 (q, J = 7.1 
Hz, 2H), 2.25 (dd, J = 7.8, 1.1 Hz, 2H), 2.14 (dd, J = 7.9, 1.3 Hz, 2H), 1.28 (t, J = 7.1 Hz, 3H), 
0.98 (d, J = 7.2 Hz, 6H) ppm; 13C NMR (101 MHz, CDCl3): δ 193.7, 166.3, 154.8, 145.0, 135.7, 
124.4, 60.4, 45.2, 44.9, 35.0, 27.1 (2C), 14.4 ppm; IR: 2957, 2924, 2853, 1718, 1692, 1653, 










3) Grubbs II, 
Crotonaldehyde
(2E,7E)-9-oxodeca-2,7-dienal: A known compound, prepared according to General Procedure 
A  starting  from  hex-5-enal  (10.0  mmol)  using  ylide  (triphenylphosphoranylidene)acetone.8 
Following Grubbs’ metathesis, purification on silica gel (10-15% EtOAC / PE) afforded 252mg 
as a yellow oil; 19% yield; 1H NMR (400 MHz, CDCl3): δ  9.51 (dd, J = 7.8, 2.4 Hz, 1H), 
6.86-6.73 (m, 2H), 6.15-6.07 (m, 2H), 2.42-2.34 (m, 2H), 2.31-2.24 (m, 5H), 1.77-1.66 (m, 2H). 
ppm; 13C NMR (101 MHz, CDCl3): δ 198.4, 193.9, 193.8, 157.3, 156.9, 146.7, 133.7, 133.6, 
132.0, 32.1, 32.1, 31.8, 27.2, 26.3, 26.1 ppm; IR: 2933, 2862, 2740, 1689, 1627, 1429, 1362, 













(2E,7E)-9-oxo-9-phenylnona-2,7-dienal: A known compound,9 prepared according to General 
Procedure  A  starting  from  hex-5-enal  (8.56  mmol)  and  using  ylide 
(phenylacylidene)triphenylphosphorane.10  Following Grubbs’ metathesis,  purification on silica 
gel (5% EtOAc / PE) afforded 1.08mg as a yellow oil; 63% yield; 1H NMR (400 MHz, CDCl3): δ 
9.49 (t, J = 6.2 Hz, 1H), 7.91-7.88 (m, 2H), 7.55-7.50 (m, 1H), 7.45-7.41 (m, 2H), 7.00 (dt, J = 
15.4, 6.8 Hz, 1H), 6.91-6.78 (m, 2H), 6.11 (ddt, J = 15.6, 7.8, 1.5 Hz, 1H), 2.40-2.26 (m, 4H), 
1.73 (quintet, J = 7.5 Hz, 2H) ppm; 13C NMR (101 MHz, CDCl3): δ 194.0, 190.6, 157.4, 148.2, 
137.9, 133.6, 132.9, 128.7, 128.6, 126.7, 77.5, 77.2, 76.8, 32.2, 26.5 ppm; IR: 3058, 2933, 2860, 








(E)-N,N-diethylocta-2,7-dienamide: As an intermediate to enal 5.13f, terminal alkene (5.13f-
int) was prepared according to General Procedure A, starting from hex-5-enal (8.0 mmol) and 
ylide  [(diethylcarbamoyl)methyl]triphenylphosphonium  chloride.11  Purification  on  silica  gel 
(15% to 25% EtOAc in PE) afforded 875 mg (5.13f-int) as a yellow oil, as the exclusive E-
isomer (56% yield);  (although the Z-isomer was formed in approximately 14% of the crude 
product mixture, it was separable by chromatography); 1H NMR (400 MHz, CDCl3): δ 6.88 (dt, J 
= 14.8, 7.3 Hz, 1H), 6.18 (dt, J = 15.0, 1.5 Hz, 1H), 5.82-5.73 (m, 1H), 5.03-4.94 (m, 2H), 3.38 
(dq, J = 23.9, 7.2 Hz, 4H), 2.24-2.18 (m, 2H), 2.08 (q, J = 7.2 Hz, 2H), 1.55 (quintet, J = 7.4 Hz, 
2H), 1.21-1.11 (m, 6H) ppm; 13C NMR (101 MHz, CDCl3): δ 165.9, 145.8, 138.4, 120.8, 115.0, 
42.2, 40.9, 33.3, 32.0, 27.7, 15.0, 13.3 ppm; IR:  3076, 2974, 2931, 1660, 1618, 1480, 1428, 











(2E,7E)-N,N-diethyl-9-oxonona-2,7-dienamide:  Prepared  according  to  step  (3)  of  General 
Procedure A using (6i) (875 mg, 4.48 mmol). Purification on silica gel (20% – 100% EtOAc / 
PE) afforded 450 mg 5.13f as a yellow oil; 45% yield; 1H NMR (400 MHz, CDCl3): δ 9.49 (d, J 
= 7.8 Hz, 1H), 6.89-6.77 (m, 2H), 6.19 (dt, J = 15.0, 1.5 Hz, 1H), 6.10 (ddt, J = 15.6, 7.9, 1.5 Hz, 
1H), 3.36 (dquintet, J = 23.3, 7.4 Hz, 4H), 2.39-2.33 (m, 2H), 2.25 (qd, J = 7.3, 1.4 Hz, 2H), 1.67 
(quintet, J = 7.4 Hz, 2H), 1.14 (dt, J = 20.3, 7.1 Hz, 6H). ppm; 13C NMR (101 MHz, CDCl3): δ 
194.0, 165.6, 157.8, 144.6, 133.5, 121.5, 42.2, 41.0, 32.2, 31.9, 26.7, 15.0, 13.3 ppm; IR: 2973, 












3) Grubbs II 2-(allyloxy)ethan-1-ol
 ethyl  (E)-4-(((E)-4-oxobut-2-en-1-yl)oxy)but-2-enoate:  Prepared  according  to  General 
Procedure  A  (step  3,  Grubbs’ metathesis  only),  from  known  starting  alkene  (ethyl  (E)-4-
(allyloxy)but-2-enoate) (970 mg, 5.7 mmol).12 Purification on silica gel (15% - 20% EtOAc / PE) 
afforded 477 mg 5.13g as a clear oil; 42% yield; 1H NMR (400 MHz, CDCl3): δ 9.59 (d, J = 7.9 
Hz, 1H), 6.94 (dt, J = 15.8, 4.2 Hz, 1H), 6.82 (dt, J = 15.8, 4.0 Hz, 1H), 6.38 (ddd, J = 15.8, 7.8, 
1.8 Hz, 1H), 6.09 (dd, J = 15.8, 1.8 Hz, 1H), 4.30 (dd, J = 3.9, 1.9 Hz, 2H), 4.23-4.18 (m, 4H), 
1.27 (dt, J = 16.6, 7.9 Hz, 3H). ppm; 13C NMR (101 MHz, CDCl3): δ 193.2, 166.2, 152.2, 143.2, 
132.0, 121.9, 69.6, 69.3, 60.7, 14.4 ppm; IR: 2983, 2906, 2850, 2728, 1720, 1692, 1447, 1368, 












ethyl (2E,7E)-2-methyl-9-oxonona-2,7-dienoate: Prepared according to General Procedure A, 
starting  from  hex-5-enal  (824  mg,  8.4  mmol)  and  using  ylide  (carbethoxyethylidene) 
triphenylphosphorane (1.2 equiv), which, after Grubbs metathesis and purification on silica gel 
(5 - 8% EtOAc / PE), afforded 758 g 5.13h as a clear oil; 43% overall yield from hex-5-enal; 1H 
NMR (400 MHz, CDCl3): δ 9.49 (d, J = 7.8 Hz, 1H), 6.82 (dt, J = 15.6, 6.7 Hz, 1H), 6.73-6.68 
(m, 1H), 6.11 (ddt, J = 15.6, 7.8, 1.5 Hz, 1H), 4.17 (q, J = 7.1 Hz, 2H), 2.39-2.33 (m, 2H), 2.22 
(qd, J = 7.4, 0.7 Hz, 2H), 1.81 (q, J = 1.1 Hz, 3H), 1.68 (q, J = 7.5 Hz, 2H), 1.27 (t, J = 7.1 Hz, 
3H). ppm; 13C NMR (101 MHz, CDCl3): δ 194.0, 168.1, 157.8, 140.6, 133.4, 128.9, 60.6, 32.3, 
28.1, 26.8, 14.4, 12.6 ppm; IR: 2923, 2850, 2734, 1692, 1462, 1367, 1261, 1172, 1109, 1022, 















ethyl (2E,8E)-10-oxodeca-2,8-dienoate: Prepared according to step (3) of General Procedure 
A  from known alkene (ethyl  (E)-nona-2,8-dienoate)  (7.24 mmol).13  Purification on silica  gel 
(7.5% EtOAc / PE) afforded 1.32 g 5.13i as a pale yellow oil; 81% yield; 1H NMR (400 MHz, 
CDCl3): δ 9.50 (d, J = 7.9 Hz, 1H), 6.93 (dt, J = 15.6, 7.0 Hz, 1H), 6.82 (dt, J = 15.6, 6.8 Hz, 
1H), 6.11 (ddd, J = 15.6, 7.8, 1.3 Hz, 1H), 5.82 (dd, J = 15.6, 1.5 Hz, 1H), 4.18 (qd, J = 7.1, 2.0 
Hz, 2H), 2.35 (q, J = 6.3 Hz, 2H), 2.23 (q, J = 6.5 Hz, 2H), 1.55 (td, J = 7.2, 3.0 Hz, 4H), 1.28 
(td, J = 7.1, 2.0 Hz, 3H) ppm; 13C NMR (101 MHz, CDCl3): δ 194.1, 166.7, 158.1, 148.5, 133.3, 
121.9, 60.4, 32.6, 31.9, 27.6, 27.4, 14.4 ppm; IR: 2982, 2934, 2859, 2733, 1717, 1690, 1654, 
1461, 1367, 1308, 1268, 1183, 1128, 1096, 1042, 978 cm-1.
199
200







ethyl 2-(2-(2-oxoethyl)cyclopentyl)acetate: Prepared according to General Procedure B from 
5.13a to give, after chromatography (10% EtOAc / PE), 18mg as a clear oil, 73% yield, d.r. = 
3:2; 1H NMR (400 MHz, CDCl3): δ 9.75 (ddd, J = 5.0, 2.4, 1.6 Hz, 1H), 4.12 (qd, J = 7.2, 2.4 
Hz, 2H), 2.64-2.12 (m, 5H), 2.00-1.79 (m, 3H), 1.75-1.55 (m, 2H), 1.38-1.21 (m, 5H); 13C NMR 
(101 MHz, CDCl3): δ 202.4, 173.2, 173.1, 60.5, 60.4, 49.1, 44.7, 42.2, 39.7, 39.4, 39.0, 36.3, 
35.6, 32.4, 32.1, 30.7, 30.7, 23.7, 22.4, 14.4, 14.4 ppm; IR: 2926, 2855, 2715, 1729, 1448,1374, 








methyl  2-(2-(2-oxoethyl)cyclopentyl)acetate:  Prepared  according  to  General  Procedure  B 
from 5.13b to give, after chromatography (15% EtOAc / PE), 16 mg as a clear oil, 69% yield, 
d.r. = 3:2; 1H NMR (400 MHz, CDCl3): δ 9.77 (ddd, J = 5.0, 2.4, 1.6 Hz, 1H), 3.68 (d, J = 2.1 
Hz, 3H), 2.65-2.15 (m, 5H), 2.02-1.81 (m, 3H), 1.75-1.59 (m, 2H), 1.39-1.22 (m, 2H) ppm; 13C 
NMR (101 MHz, CDCl3): δ 202.3, 173.63, 173.56, 51.74, 51.64, 49.1, 44.7, 42.1, 39.6, 39.06, 
38.90, 36.3, 35.3, 32.4, 32.1, 30.67, 30.65, 23.6, 22.4 ppm; IR: 2952, 2872, 2718, 1735, 1436, 








ethyl  2-(4,4-dimethyl-2-(2-oxoethyl)cyclopentyl)acetate:  Prepared  according  to  General 
Procedure B from 5.13c to give, after chromatography (6% EtOAc / PE), 18 mg as a clear oil, 
64% yield, d.r. = 3:2; 1H NMR (400 MHz, CDCl3): δ 9.75 (dt, J = 7.6, 1.8 Hz, 1H), 4.14 (qd, J = 
7.1, 2.4 Hz, 2H), 2.77-2.03 (m, 6H), 1.85-1.67 (m, 2H), 1.29-1.15 (m, 5H), 1.09-1.03 (m, 6H) 
ppm; 13C NMR (101 MHz, CDCl3): δ 202.36, 202.26, 173.17, 173.11, 60.53, 60.47, 49.0, 48.0, 
47.6, 46.93, 46.86, 45.7, 42.1, 39.6, 39.2, 37.9, 37.6, 37.4, 36.4, 35.3, 31.27, 31.13, 31.10, 30.2, 








2-(2-(2-oxopropyl)cyclopentyl)acetaldehyde:  Prepared  according  to  General  Procedure  B 
from 5.13d to give, after chromatography (15 - 20% EtOAc / PE), 12 mg as a clear oil, 57% 
yield, d.r. = 6:1; 1H NMR (400 MHz, CDCl3): δ 9.88-9.78 (m, 1H), 2.66-2.59 (m, 2H), 2.43-2.35 
(m, 2H), 2.15 (d, J = 4.4 Hz, 3H), 2.01-1.88 (m, 4H), 1.69-1.57 (m, 2H), 1.32-1.17 (m, 2H) ppm; 
13C NMR (101 MHz, CDCl3): δ 208.7, 202.5, 49.2, 49.0, 41.0, 39.8, 32.32, 32.29, 30.5, 23.7 









2-(2-(2-oxo-2-phenylethyl)cyclopentyl)acetaldehyde:  Prepared  according  to  General 
Procedure B from 5.13e to give, after chromatography (10% EtOAc / PE), 18 mg as a clear oil, 
63% yield, as a mixture of diastereomers; d.r. = 13:1; 1H NMR (400 MHz, CDCl3): δ 9.78 (t, J = 
1.9 Hz, 1H), 7.96-7.93 (m, 2H), 7.58-7.54 (m, 1H), 7.49-7.44 (m, 2H), 3.13 (dd, J = 16.5, 5.1 Hz, 
1H), 2.92 (dd, J = 16.5, 8.3 Hz, 1H), 2.68 (ddd, J = 16.7, 4.7, 1.6 Hz, 1H), 2.40 (ddd, J = 16.7, 
8.4, 2.2 Hz, 1H), 2.15-1.94 (m, 4H), 1.68-1.61 (m, 2H), 1.27 (dtt, J = 16.2, 8.1, 3.9 Hz, 2H). 
ppm; 13C NMR (101 MHz, CDCl3): δ 202.6, 200.0, 137.2, 133.2, 128.8 (2C, major + minor), 
128.2 (2C, major + minor), 49.4, 43.9, 41.5, 40.0, 32.47, 32.38, 23.8 ppm; IR: 3060, 2926, 2869, 








N,N-diethyl-2-(2-(2-oxoethyl)cyclopentyl)acetamide:  Prepared  according  to  General 
Procedure B from 5.13f to give, after chromatography (40 - 60% EtOAc / PE), 19 mg as a clear 
oil, 68% yield, d.r. = 1.3:1; 1H NMR (400 MHz, CDCl3): δ 9.77-9.72 (m, 1H), 3.41-3.26 (m, 
4H), 2.71-2.15 (m, 5H), 2.07-1.82 (m, 3H), 1.71-1.57 (m, 2H), 1.36-1.22 (m, 3H), 1.17 (t, J = 7.1 
Hz, 3H), 1.10 (t, J = 7.1 Hz, 3H) ppm; 13C NMR (101 MHz, CDCl3): δ 203.08, 202.91, 171.48, 
171.34, 49.4, 45.1, 42.29, 42.16, 40.3, 39.8, 39.1, 38.2, 36.3, 33.9, 32.60, 32.52, 30.98, 30.87, 










ethyl  2-(4-(2-oxoethyl)tetrahydrofuran-3-yl)acetate:  Prepared  according  to  General 
Procedure B from 5.13g to give, after chromatography (20-30% EtOAc / PE), 18 mg as a clear 
oil, 73% yield, d.r. = 1:1; 1H NMR (400 MHz, CDCl3): δ 9.78 (d, J = 8.0 Hz, 1H), 4.13 (qd, J = 
7.1, 3.5 Hz, 2H), 4.10-3.97 (m, 2H), 3.54-3.39 (m, 2H), 2.85-2.24 (m, 6H), 1.26 (t, J = 7.1 Hz, 
3H) ppm; 13C NMR (101 MHz, CDCl3): δ 200.9, 200.6, 172.33, 172.28, 73.15, 73.04, 72.56, 
72.50, 60.89, 60.78, 47.8, 42.7, 41.4, 39.0, 37.81, 37.71, 35.6, 33.3, 29.9, 14.3 ppm; IR: 2924, 








ethyl 2-(2-(2-oxoethyl)cyclopentyl)propanoate: Prepared according to General Procedure B 
from 5.13h to give, after chromatography (7% EtOAc / PE), 9 mg as a clear oil, 42% yield, d.r. = 
3:7  (3:7  represents  30%  of  a  single  major  diastereomer,  to  70%  of  a  mixture  of  minor 
diastereomers); 1H NMR (400 MHz, CDCl3): δ 9.78-9.55 (m, 1H), 4.19-4.09 (m, 2H), 2.63-2.00 
(m, 4H), 1.95-1.39 (m, 5H), 1.37-1.22 (m, 5H), 1.21-1.11 (m, 3H) ppm; 13C NMR (101 MHz, 
CDCl3): δ  203.4, 202.8, 202.56, 202.47, 176.5, 77.5, 77.2, 76.8, 60.51, 60.46, 60.42, 60.32, 
55.2, 50.1, 48.5, 47.1, 46.9, 43.9, 43.37, 43.33, 43.1, 42.69, 42.56, 41.37, 41.27, 36.6, 35.4, 34.3, 
32.83, 32.68, 31.24, 31.06, 30.7, 29.5, 29.0, 27.74, 27.69, 27.67, 25.4, 24.17, 24.11, 21.72, 21.65, 
17.3, 16.8, 15.86, 15.77, 14.49, 14.46, 14.40 ppm; IR: 2926, 2854, 2714, 1730, 1457, 1384, 








ethyl 2-(2-(2-oxoethyl)cyclohexyl)acetate: Prepared according to General Procedure B from 
5.13i to give, after chromatography (10% EtOAc / PE), 20 mg as a clear oil, 75% yield, d.r. = 
7:3; 1H NMR (400 MHz, CDCl3): δ 9.76-9.73 (m, 1H), 4.14-4.09 (m, 2H), 2.59-2.08 (m, 4H), 
1.78-1.07 (m, 13H) ppm; 13C NMR (101 MHz, CDCl3): δ 202.7, 202.4, 173.13, 173.08, 60.51, 
60.48, 48.6, 44.5, 39.5, 39.1, 36.9, 36.23, 36.10, 33.0, 32.6, 29.20, 29.09, 25.91, 25.86, 23.4, 
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